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Altered ovarian cancer metabolism increases the neuronal n-acetylaspartate to
promote tumor growth

Publication No._____
Behrouz Zand, M.D.
Supervisory Professor: Anil K. Sood, M.D.
Background: Altered metabolism is a well-established trait in many cancers, and is
an emerging hallmark of cancer. Recent resurgence of cancer metabolism studies
has identified dysregulated metabolic pathways that produce novel oncometabolites
in various cancers. However, large scale studies of dysregualted high grade serous
epithelial ovarian cancers (HGSOC) are unknown.
Materials and Methods:

Following IRB approval, metabolic profiling of 101

HGSOC patients and 15 normal ovaries were obtained using GC/LC mass
spectrometry from 2 U.S. academic centers to identify highly up-regulated
metabolites.

Samples from a cohort of 135 and 208 patients from a single

institution were evaluated for gene expression and protein expression of NAT8L,
respectively.

Gene expression of NAT8L and clinical outcomes were further

investigated from publicly available databases from the cancer genomics atlas
(TCGA) using www.cbioportal.org, and two previously published melanoma gene
expression profiles.

Reverse Phase Protein Array (RPPA) and gene expression

array were evaluated in HeyA8 ovarian cancer cell lines to investigate the protein
and gene expression changes associated with NAT8L siRNA. In vitro and in vivo
iv

experiments of NAT8L siRNA were investigated to evaluate its effects on cancer
proliferation, apoptosis, cell cycle, and invasion/migration.
Results: A total of 313 metabolites were identified between these two groups, of
which 172 were significantly altered (p<0.05) between HGSOC and normal ovary
tissues. NAA was one of the most significant alterations in HGSOC compared to
the normal ovary with a greater than 28 fold elevation in ovarian cancer compared
to the normal ovary (p=2.30E-11). NAA levels in HGSOC were strongly correlated
with its biosynthetic enzyme NAT8L gene expression levels (r=0.52, p<0.0001), and
not with its degradation enzyme ASPA (r= -0.11, 0= 0.30). Patients with higher
levels of NAA had worse overall survival (1295 days) compared to patients with low
NAA levels (not reached) (p= 0.038).

Two separate HGSOC gene expression

cohorts revealed that high expression of NAT8L is associated with worse median
overall survival in HGSOC (35 months, 40 months) compared to low NAT8L gene
expression (45 months, 52 months) (p= 0.03, p= 0.005).

High NAT8L protein

expression was associated with poor overall survival in ovarian cancer with 3.86
years overall survival compared to 9.09 years with low NAT8L expression
(p<0.001).

Furthermore, high NAT8L gene expression was found to have

significantly worse overall survival in invasive breast, lung squamous, colon, uterine,
melanoma and kidney renal cell cancers.
HeyA8 and A2780 cell lines showed that NAT8L siRNA significantly
increased total apoptosis compared to control (NT) siRNA by 38.53% (p<0.001) and
37.85% (p<0.001), respectively. HeyA8 cells treated with paclitaxel and NAT8L
siRNA had a 29.83% increase in apoptosis compared to paclitaxel and NT siRNA
v

treated cells (p<0.001). HEYA8 and A2780 cells treated with NAT8L siRNA had a
significantly decreased cell proliferation by 23.65% (p<0.001) and 19.13%
(p<0.001), respectively.

HEYA8 cells treated with NAT8L siRNA had an 8.4%

increase in the number of cells with G1 phase (p<0.001), and an 11.65% decrease
in the number cells in the S phase (p<0.001). Knockdown of NAT8L in HEYA8 cells
significantly decreased migration and invasion by 91% and 92%, respectively
(p<0.001).

In HEYA8 orthotopic ovarian cancer mouse models, DOPC NAT8L

siRNA had significantly decreased tumor burden by 69.17% (p<0.01), respectively.
Furthermore, NAT8L siRNA + paclitaxel had significantly less tumor burden
compared to NT siRNA (p<0.001), paclitaxel + NT siRNA (p= 0.004), and NAT8L
siRNA alone (p=0.032). We observed similar effects in A2780, SKOV3 orthotopic
ovarian cancer mouse models and orthotopic A375-SM melanoma mouse model.
Genomic analysis of HEYA8 cells transfected with NAT8L siRNA compared
to NT siRNA showed 1961 significantly different gene expression data (p<0.001).
Hierarchical cluster analysis of RPPA from NAT8L siRNA and NT siRNA had 171
significantly different protein expression data (p<0.05).

Computational network

analysis (NetWalker) showed significant decreases in a large number of genes
involved in mitosis and the M phase of the cell cycle, regulation of catabolic
processes, and regulation of cell death being altered.
Conclusion: HGSOC metabolic profiling revealed highly altered metabolism
compared to the normal ovary. NAA is one of the most up-regulated metabolites in
HGSOC. High levels of NAA are associated with worse overall survival in HGSOC.
Furthermore, high expression of its biosynthetic gene (NAT8L) is associated with

vi

worse overall survival in HGSOC, invasive breast, lung squamous, colon, uterine,
melanoma and renal cell cancers. Inhibiting NAA production decreases tumor
growth, and tilts the cancer cell to a more catabolic steady state. Therefore, our
data indicate that targeting cancer’s NAA production maybe an effective therapeutic
approach.
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Background and Introduction
Ovarian Cancer
In the U.S., ovarian cancer is the fifth most common cause of cancer related
deaths in women [1]. Approximately 22,280 women in the U.S. will be diagnosed,
and 15,500 will die in one year of ovarian cancer [1]. Despite drug developments,
ovarian cancer remains a high mortality cancer with diagnosis in late stage of
disease and high tumor burden[2].

This high mortality is due the incidence of

recurrence remaining high, and little has changed over 30 years [3,4].
Treatment of primary ovarian cancer is a combination of tumor cytoreductive
surgery and combination intravenous paclitaxel and carboplatin chemotherapy. The
role of surgery is important to extend overall survival with the ultimate goal of
cytoreduction to no residual disease [5,6,7].

Patients with primary ovarian cancer

have a 70-80% chemotherapy response rate; however, 40-50% will recur within two
years. Various chemotherapy route administration and dose adjustment have been
attempted to improve outcomes. For example, the administration of intraperitoneal
(I.P.) chemotherapy has been shown to increase overall survival in patients with
residual disease < 1 cm after surgery[8].

However, it remains controversial as

direct comparison doses to intravenous chemotherapy is not available, and toxicity
of I.P. remains a major issue[2]. Given the poor survival and high recurrence of
ovarian cancer with little improvement in patient outcomes despite cytotoxic drug
developments over the years, the focus is turning on understand the tumor biology
to identify new targets in therapy.
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Cancer Metabolism
Altered metabolism is a well-established trait in many cancers, and is an
emerging hallmark essential to cancer’s biology[9]. In order to better understand
cancer metabolism, knowledge of unicellular microbes and proliferating cell in
multicellular organisms can better illustrate the effect of environmental nutrition on
cell functioning. Under adequate nutrition availability, unicellular organisms such as
microbes and proliferating cells in multicellular organisms have evolutionary
pressure to replicate new cells.

These cells and unicellular organisms will uptake

nutrients to provide carbon, nitrogen, and free energy to build new cells. Glucose is
the main nutrient metabolized by these cells, and through glycolysis will excrete
carbons through lactate, ethanol, or other organic acids such as acetate or butyric
acid[10]. In periods of nutrient deficiency or cell starvation, these cells will alter their
metabolism to provide maximum amount of free energy for cell survival and
temporarily halt cell replication[10].
In multicellular organisms, most cells are exposed to a constant supply of
nutrients. To prevent uncontrolled cell proliferation, these cells need growth factor
stimulation of signaling receptors to stimulate uptake of nutrients.

Cancer cells

overcome this by specific gene mutations that can alter receptor signaling
pathways.

These pathways can be constitutively active allowing for constant

nutrient uptake and metabolism that promote cell survival and growth[10].
Therefore, altered cancer metabolism presents a promising approach to anti-cancer
therapy development, and this has caused a resurgence of research revealing new
metabolic pathways not seen in non-cancerous cells.
2

Glycolysis and Warburg Effect
Under adequate oxygen supply, differentiated or non-proliferating cells
metabolize glucose to CO2 by oxidizing pyruvate in the tricarboxylic acid cycle (TCA
cycle).

This results in reduction of nicotinamide adenine dinucleotide (NADH).

NADH fuels oxidative phosphorylation to maximize ATP production[10].

In

anaerobic conditions, differentiated cells primarily rely on glycolysis for energy
production, and therefore produce large amounts of lactate. However, cancer cells,
normal proliferating cells, and unicellular microbes rely heavily on glycolysis and
produce large amounts of lactate even in the presence of adequate oxygen supply.
This alteration of cell metabolism in cancer cells compared to non-cancerous cells
was first reported by Otto Warburg in 1956[11].

This “Warburg effect” of high

glucose consumption and high lactate production has clinically been taken
advantage of by fluorodeoxyglucose positron emission tomography (FDG-PET)
scans [12].
The metabolism of one molecule of glucose using oxidative phosphorylation
in the TCA cycle yields 36 ATP molecules, whereas under glycolysis, glucose only
yields 2 ATPs[13]. So why do cancer cells rely heavily on glycolysis even when
oxygenation is plentiful? One explanation is that cancer cells are highly proliferative
and require large amounts of biomass (lipids, amino acids, and nucleotides) to
divide therefore these cells demand more than just ATP. There is accumulating
evidence that a “Supply-Based” model is more likely in cancer cells [14]. In this
model, growth factor signaling directly increases nutrient uptake and alters
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metabolism to maximize biomass production independent of ATP. Thus, ATP is a
secondary process in proliferating cancer cells. An example of this is shown by Van
Heiden et al. for the major cell membrane molecule, palmitate[10].

Palmitate

synthesis requires 7 molecules of ATP, 16 carbons from 8 molecules of acetyl-coA,
and 28 electrons from 14 molecules of reduced nicotinamide adenine dinucleotide
phosphate (NADPH). A glucose molecule can either provide 36 ATPs via oxidative
phosphorylation, 30 ATPs and 2 molecules of NADPH though pentose phosphate
pathway, or 6 carbons in the form of acetyl-CoA for macromolecular synthesis.
Therefore, proliferating cells demands for glucose are inclined more for NADPH and
acetyl-CoA production for palmitate synthesis, and not ATP from oxidative
phosphorylation.

Furthermore, the commitment of glucose into maximal ATP

production by oxidative phosphorylation would increase ATP/ADP ratio therefore
inhibiting NADPH and acetyl-CoA production. Therefore, glucose consumption in
proliferating and cancer cells is more so needed for acetyl-CoA production for lipid
synthesis, diversion to PPP for ribose production for nucleotide synthesis, and
glycolytic intermediates for non-essential amino acid production.
Mitochondria and cancer
The mitochondria genome includes one to two thousand nuclear DNA gene,
and thousands of copies of mitochondrial DNA inside the mitochondria[15]. The
mitochondrial DNA contains the 13 most important genes for oxidative
phosphorylation while the nuclear DNA contains the rest including genes for
mitochondrial metabolic regulation[15].

The mitochondria has many essential

cellular functions and regulates energy production, oxidation-reduction (redox)
4

status, cytoplasmic calcium levels, reactive oxygen species (ROS) production,
biosynthetic precursors such as acetyl-CoA, and apoptosis[15]. It is clear that many
cancer cells do not have dysfunctional mitochondria as a well-functioning
mitochondrion is needed for cell viability and growth [16,17]. Mitochondrial DNA
mutations can alter cell metabolism and enhance tumorigenesis by impairing
oxidative phosphorylation and adapting the cell’s bioenergetics state for
proliferation[18]. Mutations in mitochondrial nuclear DNA genes can also contribute
to tumorigenicity.

Mutations in succinate dehydrogenase (SDH), fumurate

hydratase (FH), and IDH1 and IDH2 can increase levels of succinate, fumurate, and
R-2-hydroxyglutarate [(R)-2-HG][19,20,21].

This can inhibit various alpha-

ketoglutarate dioxygenase levels and activate NRF2 response leading to increased
tumorigenicity [20,22].
Altered cancer metabolism can increase ROS produced by mitochondria.
Mitochondrial ROS is a potent mitogen, and if apoptosis is inhibited, high ROS can
cause neoplastic transformation [23,24].

Furthermore mitochondrial ROS can

stabilize hypoxia inducible factors (HIF), nuclear factor kappa-B (NF-Kβ), and FOSJUN transcription factors thereby increasing cell proliferation [15,25].

Cancer cell

ROS can also affect the tumor microenvironment whereby it inactivates caveolin-1
in the surrounding stromal fibroblasts. This increases fibroblast mitophagy reducing
its mitochondrial function, and increases fibroblast lactate production. The over
production of lactate in fibroblasts can fuel cancer cells to aid in proliferation and
growth. [26]
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Lipogenesis in cancer
Most non-cancerous mammalian cells get lipids from the blood stream, and
de novo lipogenesis occurs mainly in liver, adipocytes, and lactating breasts[27].
Cancer cells can synthesize lipids similar to embryonic cells by reactivating de novo
lipogenesis [28,29]. The increase in lipid synthesis has important consequences to
cancer cell survival and growth.

One consequence of lipogenesis is for the

massive biomass accumulation. In fact, inhibition of lipid synthesis has been shown
to decrease cancer cell proliferation and tumor growth [30,31,32,33]. Fatty acids
contribute to phospholipids (phosphotidylcholine, phosphotidylethalamine) for cell
membrane synthesis, and phospholipids are associated with poor survival in several
cancers [34,35].
There is evidence that lipid synthesis confers resistance in cancer cells to
oxidative stress. Cancer cells have high rates of saturated and mono-unsaturated
fatty acid synthesis, and this has been shown to reduce cell death induced by
oxidative stress or chemotherapy agents[36]. Inhibition of lipid synthesis may seem
promising to combine with chemotherapy agents to improve the efficacy of its
cytotoxicity.
Increased lipid synthesis may also confer cell resistance to the effects of
energy stress.

Some tumors rely on lipid oxidation as a source of energy

production by using mitochondrial beta-oxidation to produce ATP via OXPHOS
[37,38]. Activation of beta-oxidation seems to be needed for cancer cell viability
during times of energy stress [39,40].
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The regulation of lipid synthesis is mainly done by Sterol Regulatory Element
Binding Transcription Factor (SREBPs)[41]. There are three isoforms that regulate
lipogenesis: SREBP1a, SREBP1c, and SREBP2[42]. SREBP1a is most abundant
in cultured cells [43]. Although there are overlaps, SREBP1s mainly regulate fatty
acid, phospholipid, and triaceylglyceride synthesis, and SREBP2 main regulates
cholesterol synthesis [41].

Cancer tissues show elevated level of SREBPs[27].

Regulation of SREBPs can be positively regulated by PI3K/AKT/mTOR, loss of
retinoblastoma (Rb), and mutant p53 [44,45,46]. Negative regulation of SREBPs is
seen with high phosphotidlycholine or AMPK activity [47,48].
Amino acids and Cancer metabolism
Amino acids (AA) are carbon molecules that contain amino and acid groups
that have variable side chains giving them different biochemical functions [49].
There are 300 known amino acids, but only 20 of them serve as building blocks for
proteins(Table 1) [49].

Amino acids such as ornithine, citrulline, homocysteine,

taurine, and β-alanine have major roles in cell metabolism [50,51,52,53]. Important
functions of AA catabolism leads to metabolites with important biologic functions
such as ammonia, carbon dioxide, long and short-chain fatty acids, glucose, ketone
bodies, nitric oxide, urea, uric acid, polyamines, and nitrogenous substances[49].
In addition AA can regulate gene expression and proteins signaling, synthesize
hormones and low-molecular weight nitrogenous substances, and regulate
metabolic pathways for growth and survival.
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Table 1. Twenty protein building amino acids
Essential amino acids

Non-essential amino acids

Arginine

Alanine

Histidine

Asparagine

Isoleucine

Aspartate

Leucine

Cysteine

Lysine

Glutamate

Methionine

Glutamine

Phenylalanine

Glycine

Threonine

Proline

Tryptophan

Serine

Valine

Tyrosine

AA can regulate gene expression at transcription, translation, and posttranslational protein modifications [49]. For example, methionine, glycine, serine
and histidine can methylate proteins and DNA, thus regulating gene and protein
signaling [49]. Glutamine, arginine, and leucine can stimulate mTOR1 in a cell
specific manner therefore increasing its anabolic activity of protein synthesis and
inhibiting autophagy [54,55].
AA can be precursors for low-molecular weight hormones and neurotransmitters.
Tyrosine or phenylalanine can be synthesized into epinephrine, norepinephrine,
dopamine, and thyroid hormones [49]. Tryptophan is a precursor for serotonin and
8

melatonin. Glutamate is the precursor for GABA [49]. Furthermore, high doses of
oral of intravenous AA can stimulate hormones from endocrine cells.

Arginine,

glutamine, and leucine can stimulate insulin, growth hormone, prolactin, glucagon,
progesterone, and placental lactogen [56,57].
Another important function of AA is regulating key metabolic pathways in cells.
For example, glutamate and aspartate mediate transfer of reducing equivalents
across the mitochondrial membrane via the malate-aspartate shuttle which affects
glycolysis and cell redox status. The net result of the malate-aspartate shuttle is
that NADH is transported from the cytosol into the mitochondria generating 3 ATP
molecules [58]. Another example of metabolic regulation by AA is with arginine.
Arginine increases expression of AMPK and peroxisome proliferator-activated
receptor γ co-activator 1-α (PPAR) proteins which has been shown to affect
mitochondrial energy status and rat fat mass [59].
Glutamine is one of the highest nutrients to be consumed by cancer cells.
Glutamine is a non-essential amino acid because humans are able to synthesize it
from glutamate and ammonia via the enzyme glutamine synthetase(GS)[13].
However, not all human tissues have GS therefore these tissues rely on glutamine
uptake from tissues that are able to synthesize glutamine. Glutamine can be used
in cells for protein synthesis, nucleotide synthesis, and glucosamine production[60].
Cells that are driven to growth by the oncogene MYC are particularly sensitive to
glutamine availability.

MYC driven cells will undergo apoptosis by failing

anaplerosis from glutamine derived substrates [61].
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Glutamine together with glucose provides most of the carbon and nitrogen
needed for cell replication [62].

In glioblastoma cells, approximately 60% of

glutamine and 90% of glucose can produce lactate and alanine waste. Glutamine
provides TCA intermediate alpha-ketoglutarate for anaplerosis which promotes
NADPH production via malic enzyme. Pyruvate is synthesized in this reaction which
is then converted to lactate by lactate dehydrogenase [62]. Therefore, the excess
lactate production seen in the “Warburg effect” is not only a consequence of
glucose/glycolysis, but also of the glutatmine/glutaminolysis pathway.
Although glucose is the major lipogenic precursor in cancer cells, glutamine
can also provide carbons for lipid synthesis.

14

C labeling of glutamine showed that

25% fatty acyl molecules in glioblastoma cells were derived from glutamine.
Furthermore, glutamine analplerosis provides oxaloacetate substrate that combines
with glucose derived acetyl-coA for citrate production via citrate synthetatase[62].
However, some cancer cells with mutations in TCA cycle enzymes or electron
transport chain have defective mitochondrial functioning for lipid synthesis. These
cancer cells rely on glutamine dependent reductive carboxylation for citrate
formation.

This pathway relies on cytoplasmic and mitochondria isocitrate

dehydrogenase enzyme (IDH), therefore rendering glutamine as the major source
for acetyl-coA production in lipid synthesis [63].
There is emerging evidence for the role of other amino acids and their role in
cancer progression. For example, inhibiting glycine uptake and its mitochondrial
biosynthesis impairs proliferation in cancer cells [64]. Prostate cancer cells have
high levels of the amino acid sarcosine (a glycine derivative), and high levels of
10

sarcosine lead to cancer progression and metastases [65]. Functional genomics
has shown that serine synthesis is essential for breast cancer carcinogenesis [66].
Inhibition of the isoform M2 pyruvate kinase (PKM2) leads to accumulation of
glycolytic intermediates into the serine synthesis pathway therefore maintains
mTOR1 activity [67].

Furthermore, serine starvation in p53 deficient cells resulted

in oxidative stress, reduced cell viability and increased cell proliferation [68].
Besides glucose, glutamine is also another nutrient heavily consumed by
cancer cells. Glutamine is a non-essential amino acid because humans are able to
synthesize

it

from

synthetase(GS)[13].

glutamate

and

ammonia

via

the

enzyme

glutamine

However, not all human tissues have GS therefore these

tissues rely on glutamine uptake from tissues that are able to synthesize glutamine.
Glutamine can be used in cells for protein synthesis, nucleotide synthesis, and
glucosamine production[60]. Cells that are driven to growth by the oncogene MYC
are particularly sensitive to glutamine availability. MYC driven cells will undergo
apoptosis by failing anaplerosis from glutamine derived substrates [61].
Glutamine together with glucose provides most of the carbon and nitrogen
needed for cell replication [62].

In glioblastoma cells, approximately 60% of

glutamine and 90% of glucose can produce lactate and alanine waste. Glutamine
provides TCA intermediate alpha-ketoglutarate for anaplerosis which promotes
NADPH production via malic enzyme. Pyruvate is synthesized in this reaction which
is then converted to lactate by lactate dehydrogenase [62]. Therefore, the excess
lactate production seen in the “Warburg effect” is not only a consequence of
glucose/glycolysis, but also of the glutatmine/glutaminolysis pathway.
11

Although glucose is the major lipogenic precursor in cancer cells, glutamine
can also provide carbons for lipid synthesis.

14

C labeling of glutamine showed that

25% fatty acyl molecules in glioblastoma cells were derived from glutamine.
Furthermore, glutamine analplerosis provides oxaloacetate substrate that combines
with glucose derived acetyl-coA for citrate production via citrate synthase [62].
However, some cancer cells with mutations in TCA cycle enzymes or electron
transport chain have defective mitochondrial functioning for lipid synthesis. These
cancer cells rely on glutamine dependent reductive carboxylation for citrate
formation.

This pathway relies on cytoplasmic and mitochondria isocitrate

dehydrogenase enzyme (IDH), therefore rendering glutamine as the major source
for acetyl-coA production in lipid synthesis [63].
AMPK and cell metabolism
One of the key metabolic regulators in eukaryotic cells is AMP-activated
protein kinase (AMPK)[69]. Ultimately, the role of AMPK is to balance the ratio of
ATP consumption and ATP generation.

AMPK promotes cell catabolism to

generate more ATP, and inhibits anabolic pathways[69].

AMPK can be activated

by lowering of intracellular ATP; AMP or ADP can directly bind to its regulatory
subunit causing a conformational change that protects its activating phosphorylation
[70,71]. The major phosphorylation mechanism of AMPK is by the threonine/serine
kinase Liver Kinase B1 (LKB1) at Thr172 [72,73].

AMPK can also be

phosphorylated at Thr 172 by calcium flux, independent of LKB1, by CAMKK2
(CAMKKβ) kinase [74].

The majority of AMPK regulation in cell are by LKB1,

however, CAMKK2 appears to be major AMPK regulators in T-cells and neurons
12

[75,76]. TAK1of the MAPKKK family can also activate AMPK by phosphorylating
Thr172 [77]. Additional controls of AMPK regulation are currently unknown.
In mammalian cells, AMPK can be activated by a variety of cell stresses and
variety of drugs which increase cellular levels of AMP, ADP, or calcium [78].
Metformin, the type 2 diabetes drug, can activate AMPK in a LKB1 dependent
manner[79].

Metformin indirectly causes AMPK activation by inhibiting Complex I

of the respiratory chain leading to lower ATP levels[80,81]. The AMPK agonist
AICAR is a precursor to ZMP which mimics AMP, and also indirectly activates
AMPK[82]. The chemotherapy drug pemetrexed can also result in elevated ZMP
therefore activating AMPK [83].
There is emerging evidence that AMPK can be activated independent of
AMP, ADP, or calcium. In cultured cells, AMPK is activated by reactive oxygen
species (ROS). The mechanism of action is unclear, but it has been proposed to
involve inhibition of mitochondrial ATP synthesis[80], oxidation of two conserved
cysteine residues in the AMPK alpha subunit[84], or by the protein ataxia
telangiectasia (ATM) which can phosphorylate LKB1[85]. Genotoxic agents such as
etoposide, doxorubicin, and ionizing radiation can also activate AMPK, although the
mechanism is not clear [86,87,88].
AMPK coordinates PI3K/AKT/mTOR pathway to control cell growth and
autophagy. For example, mTORC1 is tightly regulated by AMPK.

AMPK can

either phosphorylated the tumor suppressor TSC2 on serine 1387 or directly
phosphorylate Raptor (regulator associated protein of mTOR) blocking the ability of
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mTORC1 kinase to phosphorylate its substrates [89,90].

The autophagy

components ULK1 can be directly activated by AMPK or by mTORC1[91,92] .
Autophagy is activated to replenish metabolites and nutrients in times of low energy
state.

AMPK can trigger destruction of defective mitochondria though ULK1

dependent mitophagy and trigger mitochondrial biogenesis though PGC-1-alpha
transcription[69]. In hematopoietic stem cells, genetic knockout of LKB1 or AMPK
catalytic subunits caused a significant rise in defective mitochondria[93]. Therefore,
AMPK is a key regulator of mitochondrial homeostasis.
AMPK can alter cellular metabolism by directly regulating metabolic enzymes or
by altering transcription. AMPK is a key regulator of acetyl-coA carboxylase (ACC)
and HMG-coA reductase which are rate limiting steps for fatty acid and sterol
synthesis, respectively[94,95]. In fat cells, AMPK directly phosphorylates lipases
such as hormone sensitive lipase and adipocyte triglyceride lipase (ATGL)[96,97].
AMPK can regulate glucose uptake of cells by playing a key role in GLUT4
endocytic trafficking [98].

AMPK can phosphorylate a number of transcription

factors, coactivators, acetyltransferase p300, histone deacetylases, and histones
that can alter cell metabolism[69]. One example is the lipogenic transcription factor
(SREBP1) by phosphorylating a conserved serine site suppressing its activation.
SREBP1 induces expression of ACC and FASN to promote de novo lipogenesis,
and tumor growth [99,100].

AMPK can negatively regulate cAMP-regulated

transcriptional co-activators (CRTCs) and histone deacetylates(HDACs) [101,102].
Negative regulations of CRTCs have recently been shown to prolong lifespan in C.
elegans opening up a new potential of biological functions for these co-activators
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[101]. AMPK phosphorylation of HDACs in the liver can translocate to the nucleus
to deaceytlate FOXO family transcription factors and regulate glucose homeostasis
in the liver[103].

Increased expression of CRTCs and HDACs can promote tumor

progression and growth [104,105,106].
P53 and tumor metabolism
Findings from The Cancer Genome Atlas (TCGA) showed that many high
grade epithelial ovarian cancers have p53 mutations (96%), a high rate of somatic
mutations with few recurrent mutations, and high copy number alterations[107].
P53 is a tumor suppressor by two mechanisms: 1.) regulating repair and survival of
damaged cells 2.) Discarding damaged cells that cannot be repaired through
apoptosis or autophagy. Activation of p53 from DNA damage leads to G1 cell cycle
arrest and DNA repair activation. This mechanism allows to cells to resume normal
cell cycle functioning and the genomic integrity is maintained. To remove damaged
cells that can’t be repaired, p53 can activate pro-apoptotic genes such as Bax,
Noxa, and Puma. In addition to cell survival and death, p53 can also influence
cellular metabolism.
The evidence of p53 regulation of glycolysis is complex and unclear.
Emerging evidence is revealing p53 a major negative regulator of glycolysis
mediated by p53 transcriptional activation of TP53-induced glycolysis and apoptosis
regulator (TIGAR). TIGAR dephosphorylates fructose-2, 6-bisphosphate (F2-6P)
and lowers its cellular levels.

F2-6p is a potent activator of the glycolytic rate

limiting enzyme 6-phosphofructo-1-kinase (PFK-1), therefore p53 inhibits glycolysis
through this mechanism [108].

Also, p53 can down-regulate phosphoglycerate
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mutase (PGM) which converts 3-phosphoglycerate to 2-phosphoglycerate in
glycolysis, thus inhibiting glycolytic flux.

On the other hand, some studies are

showing that p53 can activate glycolysis by stimulating type II hexokinase promoter
gene expression, and this activation leads to increased tumor survival[109,110].
Clearly, further studies are needed to clarify p53’s role in glycolysis.
P53 can stimulate mitochondrial oxidative respiration by activating several
key components of the electron transport chain in cancer cell. Furthermore, p53
can increase the TCA cycle rate by activating glutaminase 2 (GLS2)[111,112].
GLS2 is a mitochondrial protein that hydrolyzes glutamine to glutamate, and
deamination of glutamate leads to alpha-ketoglutarate synthesis. Furthermore, p53
knock-out mice display impaired mitochondria respiration [112].
De novo lipogenesis has also been shown to be regulated by p53. AMPK
expression is up-regulated by p53 and this result in increased inactivation of the
lipid rate limiting enzyme ACC [102]. P53 also regulated biomass production by
inactivating glucose-6-phosphate dehydrogenase resulting in suppression of
pentose phosphate pathway and decreased NADPH production [113]. As stated
before, NADPH is critical for lipogenesis in proliferating cells. On the other hand,
emerging evidence is developing that in times of energy stress, p53 can up-regulate
fatty acid oxidation to produce ATP and NADPH further promoting cell survival and
resistance to the metabolic stress[114]. For example, a new p53 target GAMT has
been identified which is involved in the creatine pathway. GAMT is involved in p53
induced apoptosis under genotoxic stress. However, under glucose deprivation and
energy stress, p53 dependent up-regulation of GAMT induces fatty acid oxidation
16

increasing cell survival [115].

This complicated dual role of p53 in cancer

metabolism suggests that its role may be tissue and/or cancer specific. Further
understanding of various cancer types and the role of p53 in regulating its
mechanism are needed.
Targeting Cancer Metabolism
It is important to note that targeting cancer metabolism is not a new approach
in cancer therapy history. Sidney Farber noticed that adding folic acid to leukemic
cells caused an increase in cancer growth[116].

This discovery lead to the

development of the first folate analogue drug aminopterin which lead to the first
remission of Acute Lymphoblastic Leukemia[117]. Another folate analogue,
methotrexate lead to the first cure of solid tumors when administered to
choriocarcinoma patients[118].
The emerging studies of altered cancer metabolism have revealed the high
consumption of various nutrients, the increased biosynthetic pathways, and the
oncogenic signaling driving these changes are paving the way for novel approaches
to anti-cancer therapy development. For example, circulating levels of insulin and
insulin growth factor (IGF) seen in obesity and diabetes promote cancer progression
by activating cancer growth signaling [119,120,121]. Lowering blood glucose levels
is associated with improving cancer outcomes [121]. The diabetic drug Metformin is
being explored as an agent that can improve cancer outcomes. Metformin lowers
blood glucose by inhibiting mitochondrial complex I in liver which decreases ATP
production

[79,119].

This

up-regulates
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AMPK

signaling,

which

inhibits

gluconeogenesis, effectively lowering blood glucose levels and increasing insulin
sensitivity to lower circulating levels of insulin [79].
Despite driver mutations causing cancer growth and progression, there are
no effective treatments against these mutations.

Targeting metabolic enzymes

seems a promising approach to disrupt these driver mutation effects. For example
k-RAS and MYC rely on glucose and glutamine uptake for cell growth and survival,
respectively [61,122].

Disrupting glucose or glutamine uptake or their pathway

molecules in these cells can be an important approach to stopping its growth
mechanism.

Cytoxic chemotherapy can also disrupt glucose uptake, therefore

synthetic lethality approaches by combining chemotherapy and metabolic enzyme
drug targets would seem like a promising approach[119].
Ovarian cancer metabolism
Recent investigation of ovarian cancer revealed a shift in cancer metabolism
paradigm, Nieman et al. showed that ovarian cancer cells behave like parasites to
the surrounding host cells by inducing catabolic processes in the adipocytes and
tumor stroma. Ovarian cancer cells were homed to the host cells by cytokines such
as IL-8, and would increase catabolic processes such as aerobic glycolysis;
mitophagy, autophagy, and lipolysis in the host cells.

Because of this processes,

cancer cells were able to extract nutrients such as lactate, fatty acids, glutamine,
and ketones to fuel the mitochondria and promote growth and metastasis [123].
Therefore, ovarian cancer cells up-regulated their oxidative phosphorylation and
beta-oxidation to use these substrates for ATP production.
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Interestingly, the

authors saw that SKOV3ip1 cells co-cultured with adipocytes had up-regulated
AMPK, inhibition of ACC, and up-regulation of beta-oxidation in cancer cells.
RPPA analysis of primary ovarian tumors compared to omental metastasis tumor
revealed that the metastatic tumors had greater ACC phosphorylation. This was a
surprising finding given the many other results show that show up-regulation of
AMPK

and

inhibition

of

ACC

to

lead

to

decreased

tumor

growth[33,124,125,126,127].
Along with fatty acid metabolism, ovarian cancers have increased cholinecontaining metabolites [35]. These include phosphotidylcholine, phosphocholine,
glycerophosphocholine, and choline is important for many cell functions including
proliferation and cell membrane synthesis. Mechanisms behind these elevations
include choline transport, choline mediated choline kinase phosphorylation, and
activation

of

phosphotidylcholine

phospholipases.

Inhibition

of

these

phosphotidycholine metabolic pathways can inhibit tumor growth, and a novel
choline kinase inhibitor Mn58b, has shown to inhibit growth in carcinoma models
[128].
There has been one attempt at a large scale metabolic profile in ovarian
cancer, Denkert C. et al. profiled 66 ovarian cancer tissues and 9 borderline tissues
using GC/mass spectrometry. They detected 291 metabolites, but were only able to
identify 114 (39%) of these metabolites. Using a threshold of p<0.01, they were
able to identify 51 metabolites that differed from ovarian cancer and borderline
tumors. An increase in glycerolipid, purine and pyrimidine, and energy metabolism
were noted to be higher in ovarian cancer. Interestingly, several fatty acids and
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lactate were higher in borderline tumors. A major limitation of the study was that the
ovarian cancer samples included 25% non-serous tumors, and 43% of the ovarian
cancer tumors were not high grade tumors.
Oncometabolites
The recent resurgence of cancer metabolism studies has identified dysregulated
metabolic pathways that produce novel oncometabolites in cancer. Genome-wide
sequencing of glioblastoma multiforme (GBM) or WHO III and III astrocytoma and
oligodendroglioma revealed that the majority of these tumors harbor an IDH1 or
IDH2 mutation[129,130].

The two initial studies showed that IDH1 and IDH2

mutation in these patients doubled the median overall survival compared to the wild
type IDH1/2 patients [129,130]. These mutations are not only prevalent in high
grade gliomas, but also in acute myeloid leukemia [131]. These mutations cause the
loss of the cell’s ability to convert α-ketoglutarate to isocitrate when the mutant IDH
protein forms a heterodimer with the wild type IDH protein therefore inactivating the
physiologic IDH enzyme function. When the IDH mutant protein forms a homodimer
protein,

these mutations gain the ability to create the metabolite called (R)-2-

hydroxyglutarate (2HG) [21,131] from α-ketoglutarate and glutamate which can lead
to DNA hyper methylation [132,133,134].

Furthermore, studies of 2HG are

identifying that 2HG has tumorigenic properties instead of the tumor suppressive
role. Recently, high serum levels of 2HG are associated with worse overall survival
in AML [135].
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In a metabolic profile of human oligodendroglioma cells (HOG), Reitman et al
evaluated the effects of isocitrate dehydrogenase 1(IDH1-R132) and 2 (IDH2-R172)
mutations. One of the most striking findings in their study was that the levels of Nacetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) in IDH1-R132 and
IDH2-R172 cells compared with wild type IDH1 and IDH2 cells were significantly
decreased. No pathogenesis as result of low NAA or NAAG was investigated in this
study; therefore the role of NAA and NAAG is unclear in this setting. The authors
speculated that since acetyl CoA or free amino acid levels were not decreased
between the wild type and IDH mutated cells in this the HOG cells, the decreased
NAA can be a result of low NAT8L expression or high ASPA expression. In a
separate study of non-invasive detection of 2HG in WHO grade 2 and 3 glioma
patients using proton magnetic resonance spectroscopy (MRS) showed with high
sensitivity and specificity in IDH1 and IDH2 mutated gliomas had higher 2HG and
lower NAA peaks compared to wild type IDHI/2 gliomas.

Therefore, both IDH

mutation metabolic studies show that the wild type IDH1/2 gliomas lead to low 2HG
and higher NAA levels compared to the mutant IDH1/2 gliomas. With that said, the
mechanism of IDH mutation decreasing NAA levels is currently unclear and further
work is needed to provide insight into the function of NAA and 2HG in gliomas.
The neuron specific metabolite NAA
NAA is the N-acetylated amino acid aspartic acid via the amine nitrogen
group. Acetylation is the transfer of an acetyl group from acetyl-coA to another
molecule; in this case the amino acid aspartic acid accepts the acetyl group to form
NAA. The molecular weight of this compound is 175 Daltons in its ionic form. NAA
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biosynthesis occurs in neurons by the catalysis of the enzyme N-acetylaspartate
synthetase (NAT8L)[136,137]. The NAA metabolic pathway in the neuron illustrated
is discussed below (Figure 1)[138].

.
Figure 1.
Schematic presentation of NAA metabolism [138].NAA is
synthesized in the neuron via the enzyme NAT8L by acetyl-coA and aspartate.
NAA and glutamate form NAAG in an ATP dependent manner via the enzyme
NAAGS. NAAG is transported out of the neuron by an uknown mechanism to the
extra-neuronal space (ECF). NAAG is hydrolyzed into NAA and glutamate in the
ECF. Glutamate binds to the metabotropic glutamate receptor 3 (mGLuR3) to
activate the glutamatergic neurotransmission process.
NAA is taken up by
oligodendrocytes by sodium-dependent dicarboxylate transporter (NaDC3). Inside
oligodendrocytes, NAA is metabolized by aspartoacyclase (ASPA) into aspartate
and acetate. Acetate is proposed to be used for the myelin lipid synthesis.

The sources for acetyl-coA for NAA in the brain of developing rats are pyruvate
from glycolysis and 3-hydroxybutyrate (a ketone body). The aspartate arises from
aspartate transamination (AST) by using the substrates glutamate and oxaloacetate
forming aspartate and alpha-ketoglutarate [139].

The NAT8L enzyme has only

been localized in the neuronal mitochondria and microsomes (likely endoplasmic
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reticulum) [136,140,141]. NAA production is faster under high respiration energy
state than in low respiration energy state[139]. NAA production can be stimulated by
ADP, and inhibited by ATP production [142].
NAA is a major form of aspartic acid in the brain, and NAA concentrations in the
brain are on average 3-8 mM [143], making it one of the most distinct signals that is
prominent by brain magnetic resonance spectroscopy (MRS)[144,145,146] [147].
After its synthesis, NAA can bind with glutamate to form NAAG by the ATP
dependent enzyme NAAG synthetase [138]. NAAG is transported out of neuron
into the ECF where it can be hydrolyzed back into NAA and glutamate by the
membrane bound enzyme Glutamate Carboxypeptidase II (GCP-II) or CGP-III.
Genes encoding for these proteins are FOLH1 and NAALAD2, respectively. The
glutamate binds to astrocyte Glu metabotropic receptor 3 (GRM3), and is taken up
to form glutamine[147]. Furthermore, GRM3 activation can signal endothelial cells
to form new capillaries allowing for transport of glucose and oxygen to
neurons[147]. NAA is targeted towards oligodendrocytes [140], where it is taken up
by the sodium ion transporter NaDC3.
Uptake of NAA allows for its degradation into acetate and aspartate by the
enzyme aspartoacyclase (ASPA) [148]. ASPA is zinc containing carboxypeptidase
enzyme, which deacetylates NAA [149]. ASPA is present in several tissues such as
CNS, liver, and kidney in the developing rat [150]. The mammalian neurons do not
contain ASPA, therefore oligodendrocyte are where the NAA are transported to be
metabolized in the CNS [151].
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The primary function of NAA remains elusive as most studies have focused on
MRS studies compared to the biochemistry of NAA. Furthermore, almost all studies
are based on the mammalian brain.

It is proposed that NAA can function as

alternative source of acetate for lipid synthesis by transporting into oligodendrocytes
where it is broken down into acetate by ASPA for lipid synthesis [152,153,154,155].
Alternatively, NAA has been proposed to act as an osmotic regulator by transporting
water bound to NAA into ECF [156].
NAA has also been linked to ATP production, and proposed to be involved in
analplerosis [38,139,142]. This is based on the theory that depletion of aspartate
from the mitochondria would promote the kinetics of aspartate transaminase (AST)
towards aspartic acid and alpha-ketoglutarate production [148,157]. It is reasonable
to assume that all of these functions can co-exist as the consequences of NAA
biosynthesis and metabolism, and further research would help clarify NAA’s biologic
role.
More evidence of its biological role are highlighted by two inborn errors of
metabolism diseases which involve disruption of the NAA metabolic pathway. The
first is called hypoacetylaspartia characterized by the inability to biosynthesize NAA
by NAT8L.

There has been one documented case in history of a patient with

hypoacetylaspartia. This patient suffered from severe mental retardation, ataxia,
microcephaly, and seizures[158].

This patient was found to have homozygous

mutation of NAT8L [137]. In a single reported study of NAT8L knockout mice study
the focus was mainly on the social behavior of mice which showed decreased social
interaction and greater anxiety like behaviors in homozygous deleted NAT8L [159];
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no other histological or MRS detection of NAA was reported in this study limiting
any generalizability to the human condition.
The second inborn error of metabolism disease with abnormal NAA levels is
Canavan disease. Canavan disease is characterized by a lack of ASPA activity
which leads to NAA accumulation. Clinically, patients with this disease display
macrocephaly, severe cognitive and motor delay, seizures, and death by the third
decade of life [160].

The pathologic hallmark of Canavan disease is

dysmyleination, intramyelinic edema , and central white matter vacuoles[160]. The
knockout mice studies for ASPA have recapitulated the biologic effects seen in
human Canavan disease.

Homozygous (-/-) ASPA mice display failure to thrive,

macrocephaly, neurologic impairments such as tremors, abnormal gait, lethargy,
pain insensitivity, and some developed seizures by 6 months of age. MRS of the -/ASPA mice showed abnormally high levels of NAA compared to the wild type mice,
and histopathologic evaluation of the brain showed features similar to those seen in
Canavan disease [161].
NAA has recently been detected outside of the CNS [65,162,163,164].
Aspiration from ovarian tumor cysts (OTC) has been linked to be significantly higher
in the serous histology type benign, borderline, and malignant tumors [163,164],
and there was no difference between NAA levels in OTC between the malignant,
borderline, or benign serous tumors. The range of OTC NAA concentrations in
serous tumors have been reported between 5-187 µM [163,164,165]. However,
higher NAA concentrations in ovarian cyst fluid

of malignant serous ovarian

cancers have been found to be associated with advanced stage disease (Stage III
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and IV)[163]. The concentrations of NAA levels in OTC have also been found to be
relatively similar to the concentration present in malignant ascites[163].

These

findings suggest that NAA in cyst and ascites fluid are associated with higher stage
disease, and that NAA levels may be associated with worsening outcomes.
In a small study, the metabolome of normal human ovaries, primary ovarian
adenocarcinomas (POC) and metastatic omental ovarian cancer (MOC) tumors
were profiled by LC and GC mass spectrometry.

NAA and NAAG levels were

elevated by 3.5 and 2.2 fold, respectively, in POC compared to the normal ovary.
NAA and NAAG were further elevated by 85.6 and 8.5 fold, respectively, in MOC
compared to the normal ovary[162]. This indicates that NAA levels are even much
higher in the metastatic tumors compared to the primary ovarian cancer site, and
suggests that its accumulation may have a role in ovarian cancer pathogenesis.
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Hypothesis and specific aims:
Hypothesis #1: Metabolic profiling of ovarian cancer compared to the normal
ovary will identify tumor promoting metabolites
Specific Aim: Identify the most up-regulated metabolite in ovarian cancer
compared to the normal ovary in human patients and determine the consequences
to tumor growth when its production is inhibited
Hypothesis #2: High levels of NAA are associated with worse outcomes in
ovarian cancer
•

Specific Aim: Determine the clinical consequences of alterations in
the NAA pathway in ovarian cancer

Hypothesis #3: Decreasing NAA production will decrease tumor growth and
progression
•

Specific Aim: Examine the biological effects of inhibiting NAA
production by siRNA NAT8L in ovarian cancer cell proliferation,
survival, and invasion using in vitro and in vivo assays
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Methods
Clinical Analysis
After IRB approval was obtained, patients were identified at the University of
Texas at M.D. Anderson Cancer Center (MDACC) and the University of Iowa who
were diagnosed with ovarian, primary peritoneal, or fallopian tube carcinoma.
Patients were excluded if they did not receive primary therapy at the institution of
record or did not have routine follow-up at that institution. All patients were treated
by surgical cytoreduction performed by a gynecologic oncologist in addition to
adjuvant or neoadjuvant taxane- and/or platinum-based chemotherapy. Surgical
staging was performed according to International Federation of Gynecology and
Obstetrics guidelines. All treatments were administered at the institution of record.
Specimens were reviewed by a gynecological pathologist at the institution of record.
Clinical data collected included patient demographics, tumor characteristics, details
of treatment, as well as outcomes data such as progression-free interval and overall
survival. Optimal cytoreduction was defined by convention as residual disease less
than 1 cm as reported by the surgeon of record. Tissue samples were obtained at
the time of primary evaluation surgery. Patients who were known to be alive and/or
progression-free at the time of last contact were censored accordingly. KaplanMeier survival curves were generated and compared using a 2-sided log-rank
statistic.
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Metabolic profiling
Sample Preparation: Ovarian cancer tissue and normal ovary samples were
stored at -80oC. At the time of analysis, samples were extracted and prepared for
analysis using a standard solvent extraction method.

The sample preparation

process was carried out using the automated MicroLab STAR® system from
Hamilton Company. Recovery standards were added prior to the first step in the
extraction process for QC purposes. Sample preparation was conducted using a
proprietary series of organic and aqueous extractions to remove the protein fraction
while allowing maximum recovery of small molecules. The resulting extract was
divided into two fractions; one for analysis by LC and one for analysis by GC.
Samples were placed briefly on a TurboVap® (Zymark) to remove the organic
solvent. Each sample was then frozen and dried under vacuum. Samples were
then prepared for the appropriate instrument, either LC/MS or GC/MS.
Liquid chromatography/Mass Spectrometry (LC/MS): The LC/MS portion of
the platform was based on a Waters ACQUITY UPLC and a Thermo-Finnigan LTQ
mass spectrometer, which consisted of an electrospray ionization (ESI) source and
linear ion-trap (LIT) mass analyzer. The sample extract was split into two aliquots,
dried, then reconstituted in acidic or basic LC-compatible solvents, each of which
contained 11 or more injection standards at fixed concentrations. One aliquot was
analyzed using acidic positive ion optimized conditions and the other using basic
negative ion optimized conditions in two independent injections using separate
dedicated columns. Extracts reconstituted in acidic conditions were gradient eluted
using water and methanol both containing 0.1% Formic acid, while the basic
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extracts,

which

also

used

water/methanol,

contained

6.5mM

Ammonium

Bicarbonate. The MS analysis alternated between MS and data-dependent MS
scans using dynamic exclusion.
Gas chromatography/Mass Spectrometry (GC/MS):

The samples

destined for GC/MS analysis were re-dried under vacuum desiccation for a
minimum of 24 hours prior to being derivatized under dried nitrogen using
bistrimethyl-silyl-triflouroacetamide (BSTFA). The GC column was 5% phenyl
and the temperature ramp is from 40° to 300° C in a 16 minute period.
Samples were analyzed on a Thermo-Finnigan Trace DSQ fast-scanning
single-quadrupole mass spectrometer using electron impact ionization. The
instrument was tuned and calibrated for mass resolution and mass accuracy
on a daily basis. The information output from the raw data files was
automatically extracted as discussed below.
Accurate

Mass

Determination

and

MS/MS

fragmentation

(LC/MS),

(LC/MS/MS): The LC/MS portion of the platform was based on a Waters ACQUITY
UPLC and a Thermo-Finnigan LTQ-FT mass spectrometer, which had a linear iontrap (LIT) front end and a Fourier transform ion cyclotron resonance (FT-ICR) mass
spectrometer backend.

For ions with counts greater than 2 million, an accurate

mass measurement could be performed. Accurate mass measurements could be
made on the parent ion as well as fragments. The typical mass error was less than
5 ppm. Ions with less than two million counts require a greater amount of effort to
characterize. Fragmentation spectra (MS/MS) were typically generated in data
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dependent manner, but if necessary, targeted MS/MS could be employed, such as
in the case of lower level signals.
Bioinformatics: The informatics system consisted of four major components,
the Laboratory Information Management System (LIMS), the data extraction and
peak-identification software, data processing tools for QC and compound
identification, and a collection of information interpretation and visualization tools for
use by data analysts. The hardware and software foundations for these informatics
components were the LAN backbone, and a database server running Oracle
10.2.0.1 Enterprise Edition.
Compound identification:

Compounds were identified by comparison to

library entries of purified standards or recurrent unknown entities. Identification of
known chemical entities was based on comparison to metabolomics library entries
of purified standards. As of this writing, more than 1000 commercially available
purified standard compounds had been acquired registered into LIMS for
distribution to both the LC and GC platforms for determination of their analytical
characteristics. The combination of chromatographic properties and mass spectra
gave an indication of a match to the specific compound or an isobaric entity.
Additional entities could be identified by virtue of their recurrent nature (both
chromatographic and mass spectral). These compounds have the potential to be
identified by future acquisition of a matching purified standard or by classical
structural analysis.

31

Normalization: For studies spanning multiple days, a data normalization step
was performed to correct variation resulting from instrument inter-day tuning
differences.

Essentially, each compound was corrected in run-day blocks by

registering the medians to equal one (1.00) and normalizing each data point
proportionately. For studies that did not require more than one day of analysis, no
normalization is necessary, other than for purposes of data visualization.
Metabolite statistics: All Wilcoxon rank-sum tests and t-tests are two-sided
using a threshold of P < 0.05 for significance. Class-specific metabolomics patterns
were visualized using heat maps. Unsupervised clustering of samples using
metabolomics signatures was performed using Cluster and TreeView, and
visualized using heat maps.
NAT8L gene expression:
To determine NAT8L gene expression across different cancer types, RNA
expression of 20 cancer types were analyzed by RNASeqV2 data available from the
open access TCGA web page as of Jan 18, 2013 were accessed. The normalized
counts were log2 transformed (after adding 1) to emphasize differences on a
multiplicative scale. The copy number data was analyzed as well using all of the
public level 3 data available as of Oct 30, 2012.
To determine gene expression of NAT8L’s association with clinical
outcomes, RNA expression data was analyzed by RNASeqV2 data available from
the open access TCGA web site www.cbioportal.org
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as of April 2013 were

accessed. Overall survival was analyzed by best cut-off method on provisional
databases, and based on all tumors from each query.
To validate gene expression data from non-TCGA cohorts, clinical
information CEL (Affymetrix U133Plus2)) arrays files from the publication by Tinker
et al. [166] were analyzed to validate ovarian cancer NAT8L outcomes.

To

determine NAT8L gene expression’s association with melanoma outcomes, clinical
information CEL (Affymetrix U133Plus2)) arrays files from the publication Bogunovic
et al.[167] was accessed for analysis. Also, clinical information and expression
values from melanoma samples profiled with Illumina arrays by Jonsson G et
al.[168]

were analyzed.

All analyses were performed in R (version 2.14.2)

(http:///www.r-project.org/).

The RMA gene expression values were analyzed, and

best cut off method to identify clinical outcomes. For survival analysis the patients
were grouped into percentiles according to NAT8L expression. Gene expression by
best cut-off was done to optimally split the samples into two groups. The Log-rank
test was employed to determine the significance of the association between NAT8L
expression and overall survival. The Kaplan-Meyer method was used to generate
survival curves.
Immunohistochemistry
Immunohistochemical (IHC) analysis was done on formalin-fixed, paraffinembedded samples, using standard techniques. For NAT8L, antigen retrieval was in
citrate buffer for 45 minutes in an atmospheric pressure steamer, using anti-NAT8L
antibody (Sigma-Aldrich) at 1:100 dilution was incubated overnight at 4°C. Primary
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antibody detection was with Biotenelatled HRP polymer for 6 minutes at room
temperature, followed by diaminobenzidine incubation. After IHC staining, a semiquantitative H-score was done. Briefly, the intensity of tumor cells positive for
NAT8L was 1= weak, 2 = moderate, or 3= strong intensity. NAT8L counted and
expressed as a percentage of all tumor cells by an examiner blinded to clinical
outcome. Patient samples were categorized as having low (<25%) =1, intermediate
(25 %< x<75%) =2 or high (>75%) =3. The product of percentage of cell score and
intensity score equaled the H-Score.

The IHC analysis was done on samples

collected at primary debulking surgery on 209 untreated patients with stage III–IV,
high-grade papillary serous adenocarcinoma; with institutional review board
approval, clinical information was collected. Progression-free and overall survival
were plotted with the Kaplan–Meier method for patients in each group of NAT8L
expression and compared with the log-rank statistic.
Gene Array
Gene array data from HeyA8 ovarian cancer cells double transfected with NAT8L
siRNA and NT siRNA were deposited into the GEO database.

Array data

processing was performed on Illumina BeadStudio software. We normalized gene
expression data using Quantile normalization and log2 transformation. To export to
a data matrix, Sample Gene Profile option of this software was used. BRBArrayTools were primarily used to identify genes differentially expressed between
the 2 subgroups [169], and all other statistical analyses were performed in the R
language environment. Gene expression differences were considered significant
if P values were less than 0.001. A random-walk based network scoring method,
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NetWalker, for genomic data analysis was employed (Komurov, White et al 2010).
The replicates in gene expression array (siRNA NAT8L in HeyA8) were averaged
and the ratio of average siRNA NATBL/average Control in HeyA8 was considered.
The gene names were converted into HUGO formats. Unbiased network of the top
down and up regulating genes (considered around top 100 interactions) is displayed
by running NetWalker on the entire gene set.
Reverse Phase Protein Array
HeyA8 cell lines were double transfected with NAT8L siRNA and NT siRNA.
Cellular proteins were denatured by 1% SDS (with beta-mercaptoethanol) and
diluted in five 2-fold serial dilutions in dilution buffer (lysis buffer containing 1%
SDS). Serial diluted lysates were arrayed on nitrocellulose-coated slides (Grace
Biolab) by Aushon 2470 Arrayer (Aushon BioSystems). Total 5808 array spots were
arranged on each slide including the spots corresponding to positive and negative
controls prepared from mixed cell lysates or dilution buffer, respectively.
Each slide was probed with a validated primary antibody plus a biotinconjugated secondary antibody. Only antibodies with a Pearson correlation
coefficient between RPPA and western blotting of greater than 0.8 were used in
reverse phase protein array study. Antibodies with a single or dominant band on
western blotting were further assessed by direct comparison to RPPA using cell
lines with differential protein expression or modulated with ligands/inhibitors or
siRNA for phospho- or structural proteins, respectively.
The signal obtained was amplified using a Dako Cytomation–catalyzed
system (Dako) and visualized by DAB colorimetric reaction. The slides were
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scanned, analyzed, and quantified using a customerized-software Microvigene
(VigeneTech Inc.) to generate spot intensity.
Each dilution curve was fitted with a logistic model (“Supercurve Fitting”
developed by the Department of Bioinformatics and Computational Biology in MD
Anderson Cancer Center, “http://bioinformatics.mdanderson.org/OOMPA”). This fits
a single curve using all the samples (i.e., dilution series) on a slide with the signal
intensity as the response variable and the dilution steps are independent variable.
The fitted curve is plotted with the signal intensities – both observed and fitted - on
the y-axis and the log2-concentration of proteins on the x-axis for diagnostic
purposes. The protein concentrations of each set of slides were then normalized by
median polish, which was corrected across samples by the linear expression values
using the median expression levels of all antibody experiments to calculate a
loading correction factor for each sample. "Linear after normalization" values were
transformed to Log2 values and median centered for hierarchical clustering
analysis.

Heatmaps

for

unsupervised

hierarchical

clustering

(antibody

unsupervised but samples in order for reference). The heatmap was generated in
Cluster 3.0 (http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm) as a
hierarchical cluster using Pearson correlation and a centered metric. The resulting
heat map was visualized in Treeview (http://www.eisenlab.org/eisen).
Network of the top up and down regulating proteins and phosphorylated
proteins was displayed. The protein names were converted into HUGO formats.
NetWalker was used to display the network of the proteins in red-green colormap
and the phosphor-proteins in the yellow-blue colormap. Note that if for some
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protein the total and phosphor both were down (or up, respectively) then the color is
dominated by the level of the total protein. The RPPA data was median centered
and the ratio of the NAT8L/Control was considered to draw these networks.
Cell lines and culture conditions
The derivation of the human ovarian cancer cell lines A2780, HeyA8, SKOV3IP1, are previously reported [170,171,172,173,174]. The cell lines A2780, HeyA8,
and SKOV3-IP1 were maintained in RPMI-1640 medium with 15% Fetal Bovine
Serum (FBS). HeyA8-MDR and SKOV3-TR are taxane-resistant derivations of
HeyA8 and SKOV3ip1 (Dr. Isaiah J. Fidler, MDACC, Houston, TX). The taxaneresistant phenotype was maintained by adding 300 ng/mL (HeyA8-MDR) and 100
ng/mL (SKOV3-TR) of paclitaxel to the media used for HeyA8 and SKOV3-ip1. The
human melanoma cell line A375SM was established from pooled lung metastases
produced by A375-P cells injected intravenously into nude mice [175]. These cells
were maintained in Eagle's minimal essential medium supplemented with 10% fetal
bovine serum (FBS)[176]. The melanoma cell lines UACC 62, UACC 257, and M14
were obtained from Dr. Suhendan Ekmekcioglu (The University of Texas-MD
Anderson Cancer Center; Houston, Texas), and were maintained in MEM
supplemented with 10% fetal bovine serum, 100 μg/ml glutamine, penicillin (100
units/mL), and streptomycin (100 μg/mL) (Invitrogen, Carlsbad, CA). The Ishikawa
human endometrial cancer cell line was maintained in MEM supplemented with
10% FBS and 0.1% gentamicin sulfate (gift from Dr. Russell Broaddus, MDACC,
Houston, TX) [177]. Cell lines were also routinely tested to confirm absence of
Mycoplasma. Cells were maintained at 37°C in a humidified incubator infused with
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20% O2 and 5% CO2.
Orthotopic model of ovarian cancer and melanoma in nude mice
Female athymic nude (NCr-nu) were purchased from Taconic Farms, Inc.
(Rockville, MD). The development and characterization of the orthotopic mouse
model of ovarian cancer has been previously described [178,179,180]. Briefly,
SKOV3-IP1 (1 x 106), A2780 (1 x 106), HeyA8 (0.25 x 106) human ovarian cancer
cells were lifted with trypsin/edta, washed with PBS, and resuspended in 200 µL of
Hank’s balanced salt solution (HBSS, Mediatech, Inc. Manassas, VA) and were
injected into the peritoneal cavity of female nude mice. A375-SM subcutaneous
tumors were produced by injecting 1 × 106 cells/0.2 ml HBSS over the right hip
region of the mice. Growth of subcutaneous tumors was monitored by weekly
examination of the mice and measurement of tumors with calipers. All cell lines
have been shown to reliably form macroscopic tumor implants on peritoneal
surfaces throughout the pelvis and abdominal cavity.
Tumor weight was recorded at the time of necropsy and tumor tissue was
harvested for histopatholoigcal analysis.

Proliferation index and apoptosis were

evaluated in tumor sections with immunohistochemical staining for Ki67 and
cleaved caspase-3 antigens, respectively. Frozen sections were fixed in acetone +
chloroform 1:1 for 5 minutes between two 5 minute incubations in cold acetone
alone. Endogenous peroxidases and non-specific epitopes were blocked with 3%
H2O2 in PBS and 5% normal horse serum + 1% normal goat serum in PBS,
respectively. Sections were then incubated with primary antibody directed against
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either Ki-67 (1:200, Neomarker, Fremont, CA) or CD31 (1:800, Cell Signaling,
Danvers, MA) at 4°C overnight. After washing with PBS, the appropriate HRPconjugated secondary antibody in blocking solution was added for 1 hour at room
temperature. Slides were developed with 3, 3’-diaminobenzidine (DAB) chromogen
(Invitrogen, Carlsbad, CA) and counterstained with Gil No.3 hematoxylin (SigmaAldrich, St. Louis, MO).

Proliferative index and cleaved caspase 3 index was

calculated by dividing the number of positive nuclei (brown) or by the total number
of cells for each of 5 randomly selected 200x high power fields per tumor specimen
for each treatment group.
Forward transfection
In the case of forward transfection, 6-well plates were inoculated with
150,000 cancer cells per well with a goal of transfection at 50% confluence within
12-24 hours of plating. Based on validation experiments, the appropriate amount of
the siRNA of choice was incubated for 20 minutes at room temperature in serumfree culture medium (1 mL/well) with Lipofectamine 2000 (Invitrogen, Carlsbad, CA)
at a 3:1 ratio of volume (µL) Lipofectamine 2000 to microgram siRNA. After
incubation, siRNA/Lipofectamine-containing medium were added to cells and media
to achieve a siRNA concentration of 50 nM. Cells and transfection media were
incubated at 37oC for 4 hours, and then transfection medium was changed to
serum-containing medium.
Reverse transfection
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In the case of reverse transfection, and based on previously performed
validation experiments, the appropriate amount of the siRNA of choice was
incubated for 20 minutes at room temperature in serum-free culture medium (500
mcL/well) with Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) at a 5:1 ratio of
volume of Lipofectamine RNAiMAX to mcL siRNA. After incubation, 500 mcL of the
solution was placed in each well, and then 75,000 cancer cells in 2.5 mL of serumfree media were added to each well to achieve a final siRNA concentration of 50
nM. Cells were incubated with the transfection medium for 4-6 hours at 37oC, and
then medium was changed to serum-containing medium.
Double transfection
If a longer duration of mRNA knockdown was needed than was offered by
single forward or reverse transfection, then sequential double transfection was
used. In this case, forward transfection was initially performed, and 72 hours later, a
reverse transfection was performed.
RNA Extraction
Total RNA was extracted from cells growing in vitro using RNeasy Kit (Quiagen,
Venlo, Netherlands). Cells were lifted with trypsin/edta, washed with PBS, and
centrifuged at 10,000 rpm for 5 minutes to form the pellet. The supernatant was
discarded, and RNA was extracted according to the company protocol. RNA was
quantified using a spectrophotometer and 1 µg was transcribed into complementary
DNA (cDNA) using the Verso cDNA kit (Thermo Fisher Scientific), closely following
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the manufacturer’s protocol. Quantitative RT PCR was then used to assess levels
of expression.
In vitro apoptosis
Cells were plated in 6-well plates at 150,000 cells per plate, targeting
approximately 50% confluence in serum-containing medium.

After two rounds of

transfection with siRNA (144 hours), cell viability was assessed using Annexin V
and 7-amino-actinomycin-D (7AAD) staining (BD PharmingenTM, Franklin Lakes,
NJ) by flow cytometry. Briefly, cells were harvested, washed in PBS, and incubated
with PE-Annexin V and 7AAD according to package insert instructions for 20
minutes prior to flow cytometric analysis.
In vitro proliferation
Cells were plated in 6-well plates at 150,000 cells per plate, targeting
approximately 50% confluence in serum-containing medium. After two rounds of
siRNA transfection at time point 96 hours, the percentages of cells proliferating
(defined as S-phase) were determined using the Click-iT EdU flow cytometry kit
(Invitrogen, Carlsbad, CA). Cells were incubated with 10 mcM 5-ethynyl-2deoxyuridine (EdU) for 2 hours, lifted, and washed with 1% bovine serum antigen in
d-PBS. Cells were fixed with 4% paraformaldehyde in d-PBS for 15 minutes at room
temperature and then maintained at 4oC protected from light until the time of flow
cytometric analysis, duration not to exceed 7 days. On the day of analysis, cells
were washed in 1% BSA in d-PBS and then permeabilized with 1x saponin-based
reagent for 15 minutes at room temperature. The cells were then incubated with a
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solution of 1x reaction buffer, CuSO4, Alexa-Fluor 488 azide dye, and proprietary
reaction buffer additive for 30 minutes at room temperature prior to flow cytometric
analysis.
In vitro cell cycle
For cell-cycle analysis, cells were transfected with siRNA as described for 48
hours, trypsinized, washed in PBS, and fixed in 75% ethanol overnight. Cells were
then centrifuged, washed twice in PBS, and reconstituted in PBS with 50 μg/mL of
propidium iodide. Propidium iodide fluorescence was assessed by flow cytometry.
In vitro invasion and migration
A polycarbonate membrane with 10-μm pores (Osmonics, Livermore, CA)
was uniformly coated with a defined basement membrane matrix consisting of
human laminin/type IV collagen/gelatin and used as the intervening barrier to
invasion. The bottom well contained 500 µl of 5% FBS media. Cancer cells were
added to the top wells with approximately 100,000 cells/well in serum free media.
After 24-hour incubation in a humidified incubator at 37°C with 5% CO2, cells that
had invaded through the basement membrane were collected, stained, and counted
by light microscopy[181]. Motility (migration) was determined in membrane invasion
culture system chambers containing polycarbonate filter (with 10 μm pores) that had
been soaked in 0.1% gelatin. Tumor cells (5 × 104) were seeded in each upper well,
allowed to incubate at 37°C for 6 hours in complete media, and subsequently
processed as described for the invasion assay.
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Results
Metabolic Profile of high grade serous epithelial ovarian cancer
To evaluate the global metabolic profile of human epithelial ovarian cancer
(n=71) tissues and normal non-cancerous ovarian tissue (n= 15), we used both
liquid and gas chromatography coupled with mass spectrometry to identify relative
metabolite levels. A total of 313 metabolites were identified between these two
groups (Figure 2), of which 172 were significantly altered (p<0.05) between ovarian
cancer tissues and normal ovary tissues. Of those 172 significantly altered
metabolites, 142 were elevated and 30 were decreased in ovarian cancer. For
visualizing the relationship between the 172 altered metabolites, hierarchical
clustering was used to arrange the metabolites on the basis of their relative
abundance levels across samples (Figure 3).
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Figure 2. Global metabolic profile of ovarian cancer and normal ovary.
Hierarchical clustering of 313 metabolites identified in LC/MS and GC/ MS
metabolic progiling of ovarian cancer (n= 72) and normal ovarian sample (n= 15).
Analysis reported with relative intensity to the median value for each metabolite set
to 1.
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Figure 3. Significantly altered metabolites in ovarian cancer.
Hierarchical clustering of 172 significantly altered metabolites (p<0.05).
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Of the 142 metabolites that were significantly up-regulated, the majority involved
the lipid pathway (53.5%); this was followed by amino acid (19.0%), carbohydrate
(9.9%), and nucleotide metabolic pathways (9.2%) (Figure 4).

Figure 4. Pathways affected by altered metabolism in ovarian cancer.

Although lactate levels were not significantly elevated in ovarian cancer as
compared to the normal ovary, the changes observed in the glycolytic intermediates
was consistent with increased glucose metabolism in ovarian cancer. Increased
levels of 6-carbon glycolytic intermediates glucose-6-phosphate (G6P) and fructose6-phosphate (F6P) reflect increased utilization of intracellular glucose, while
decreased levels of glucose, 3-phosphoglycerate (3-PG), 2-phosphoglycerate (2PG) and phosphoenolpyruvate (PEP) suggest increased glycolytic activity with
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contributions to lipid, amino acid, and nucleotide synthesis through pentose
phosphate pathway (Figure 5).

Figure 5. Increased glucose metabolism in ovarian cancer. Values are mean
values of the relative intensity ± SEM.
Indeed, ovarian cancer revealed low 6-phosphogluconate, and elevated
ribose-5-phosphate, and sedoheptulose-7-phosphate further suggesting increased
activity of the pentose phosphate pathway (PPP) to promote NADPH production
and nucleotide synthesis (Figure 6).
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Figure 6. Increased PPP metabolism in ovarian cancer.
values of the relative intensity ± SEM.

Values are mean

The major pathway altered in ovarian cancer from the normal ovary was the
lipid pathway.

Ovarian cancer showed significantly elevated levels for essentially

all long-chain fatty acids, with the notable exception of arachidonate and adrenate
(Table 2).
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Table 2. Elevation of long-chain fatty acids in ovarian cancer. Fold changes
are the mean relative values of ovarian cancer over the normal ovary. NS is
p>0.05.
Metabolite

Fold Change

p-value

conjugated linoleate
eicosenoate (20:1n9 or 11)
10-nonadecenoate (19:1n9)
behenate (22:0)
docosadienoate (22:2n6)
dihomo-linoleate (20:2n6)
palmitoleate (16:1n7)
10-heptadecenoate (17:1n7)
docosatrienoate (22:3n3)
oleate (18:1n9)
myristoleate (14:1n5)
nonadecanoate (19:0)
stearidonate (18:4n3)
margarate (17:0)
adrenate (22:4n6)
pentadecanoate (15:0)
myristate (14:0)
palmitate (16:0)
arachidonate (20:4n6)
stearate (18:0)

4.19
3.50
3.06
2.81
2.61
2.33
2.24
2.18
2.10
1.89
1.73
1.72
1.67
1.66
1.46
1.44
1.39
1.38
1.24
1.20

1.86E-05
1.32E-06
5.70E-06
6.10E-05
0.0002
0.0005
2.33E-05
4.39E-05
0.0148
0.0004
0.0002
2.07E-10
NS
1.80E-06
NS
0.0306
0.0053
0.0027
NS
0.0073

The most up-regulated long chain fatty acid was the bacterial gut derived
conjugated linoleate (Fold change 4.19, p-value 1.86E-05). Also, odd-numbered
carbon chain fatty acids such as pentadecanoate and margarate, and both
saturated (e.g. palmitate and stearate) and unsaturated (e.g. palmitoleate and
oleate) fatty acids were elevated.

Interestingly, in ovarian cancer, there are

significantly increased levels of the essential fatty acids linoleic acid (n-6), and
linolenic acid (n-3) (Figure 7). Importantly, n-6 and n-3 levels are the precursors for
prostaglandins, thromboxanes, leukotrienes, hydroxy fatty acids, and lipoxins[182].
Higher levels of these compounds are associated with a pro-inflammatory state in
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cancer. Indeed, a significant up-regulation of eicosanoids were seen in the ovarian
cancer samples compared to the normal ovarian tissue with prostaglandin E2 being
the highest up-regulated eicosanoid (Fold change 15.15, p-value: 4.09E-08) (Table
3).

Figure 7. Elevated levels of the essential fatty acids, linoleic acid (n-6) and
linolenic acid (n-3), in ovarian cancer . Values are relative scaled intensity mean
values±SEM.
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Table 3. Up-regulation of eicosanoids in ovarian cancer. Fold changes are the
mean relative values of ovarian cancer over the normal ovary. NS is p>0.05.

Metabolite

Fold Change

p-value

prostaglandin E2
6-keto prostaglandin F1alpha
prostaglandin I2
prostaglandin A2
15-HETE
prostaglandin D2
prostaglandin E1
thromboxane B2

15.15
11.12
8.25
6.80
6.28
5.87
5.04
2.57

4.09E-08
1.88E-06
8.21E-06
5.14E-05
8.81E-05
1.00E-04
1.05E-06
1.72E-06

Along with the up-regulated fatty acids and eicosanoids in the lipid pathway, a
similar lipid profile was seen with multiple components of the phospholipid
biosynthetic pathways to support elevated membrane demands of cancer. There
were significantly elevated levels of the membrane phospholipid precursor
compounds such as choline, ethanolamine, and cytidine 5'-diphosphocholine
(CDP-choline),

and

multiple

phospholipid

biosynthesis

lysophospholipid
(e.g.

intermediates

in

membrane

2-myristoylglycerophosphocholine,

2-

palmitoleoylglycerophosphoethanolamine, and 1-stearoylglycerophosphoinositol).
These changes along with changes in cholesterol metabolism together indicate the
massively altered membrane phospholipid metabolism in cancer.
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Brain specific N-acetylaspartate (NAA) is one of the highest up-regulated
metabolites in ovarian cancer
For further evaluation of each individual of the 142 metabolites that were
significantly up-regulated, we narrowed our list to the 20 highest fold changes of
metabolites in ovarian cancer (Table 4).
Table 4. Twenty highest up-regulated metabolites in ovarian cancer. Fold
changes are the mean relative values of ovarian cancer over the normal ovary.

Metabolic

Fold
Metabolite

p-value

Pathway
Nucloetide
Lipids
Amino Acid
Lipids
Lipids
Amino Acid
Lipids
Amino Acid
Lipids
Carbohydrates
Amino Acid
Lipids
Lipids
Lipids
Nucloetide
Lipids
Lipids
Lipids
Amino Acid
Lipids

Change
adenosine 5'-monophosphate (AMP)
CDP-choline
N-acetylaspartate (NAA)
2-oleoylglycerophosphocholine
prostaglandin E2
5-methylthioadenosine (MTA)
6-keto prostaglandin F1alpha
gamma-aminobutyrate (GABA)
1-palmitoylglycerophosphocholine
UDP-glucuronate
N-acetyl-aspartyl-glutamate (NAAG)
1-oleoylglycerophosphocholine
2-palmitoylglycerophosphocholine
prostaglandin I2
thymine
2-arachidonoylglycerophosphocholine
prostaglandin A2
1,2-propanediol
4-hydroxyphenylpyruvate
15-HETE

58.54
30.38
28.38
19.4
15.15
13.13
11.12
11.07
10.19
9.27
9.14
9.07
8.38
8.25
7.83
7.72
6.8
6.77
6.63
6.28

2.53E-06
1.00E-16
2.30E-11
1.13E-10
4.09E-08
3.94E-12
1.88E-06
0.001
6.06E-06
3.10E-09
3.51E-10
1.39E-07
2.91E-07
8.21E-06
8.27E-07
8.93E-05
5.14E-05
0.0105
9.23E-08
8.81E-05

Again, the majority of the highest up-regulated metabolites involved lipid and
amino acid pathways. The highest fold change was the nucleotide and energy
signaling molecule adenosine 5'-monophosphate (AMP), followed by the lipid
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membrane precursor CDP-choline, and NAA. Since these fold changes were based
on mean values, and there are skewed distributions across metabolites,

we

analyzed the median values of the top 8 up-regulated metabolites from table 1 to
further determine which metabolites are consistently more abundant in ovarian
cancer. Of these 8, NAA had the highest median level in ovarian cancer (Figure 8).

Figure 8. Median levels of the highest fold-change metabolites in ovarian
cancer and in the normal ovary.
NAA was one of the most significant alterations in ovarian cancer tissues
compared to the normal ovary. NAA was greater than 28 fold up-regulated in
ovarian cancer compared to the normal ovary (2.30E-11) (Table 4). NAA levels in
ovarian cancer tumors were strongly positively correlated with the brain dipeptide N53

acetyl-aspartyl-glutamate (NAAG) (r=0.85, p<0.001), along with several eicosanoids
including prostaglandins E1 (r= 0.54, p<0.001) and E2 (r= 0.50, p<0.001), the TCA
cycle substrate malate (r= 0.45, p<0.001), and AMP (r= 0.40, p<0.001) (Table 5).
NAAG was greater than 9 fold elevated in ovarian cancer (p<3.51E-10) (Table 4).
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Table 5. Metabolites associated with NAA levels. List of metabolites that were
strongly significantly associated with NAA levels.

Metabolite
N-acetyl-aspartyl-glutamate
(NAAG)
prostaglandin E1
6-keto prostaglandin F1-alpha
homocysteine
prostaglandin E2
prostaglandin I2
malate
thromboxane B2
nicotinamide

SuperPathway

Spearmon’s
r

p-value

Amino acid

0.85

<0.001

Lipid
Lipid
Amino acid
Lipid
Lipid
Energy
Lipid
Cofactors and
vitamins
Peptide
Lipid
Lipid
Amino acid
Amino acid

0.54
0.52
0.51
0.50
0.46
0.45
0.44

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

0.44

<0.001

0.44
0.42
0.42
0.41
0.41

<0.001
<0.001
<0.001
<0.001
<0.001

0.40

<0.001

gamma-glutamylalanine
prostaglandin D2
inositol 1-phosphate (I1P)
phenyllactate (PLA)
3-(4-hydroxyphenyl)lactate
adenosine
5'-monophosphate
Nucleotide
(AMP)

As mentioned, there are several known biochemical reactions that form and
breakdown NAA (Figure 9). The main biosynthetic enzyme for NAA is Aspartate Nacetyltransferase (NAT8L). The substrates for the NAT8L enzyme are acetyl-coA
and aspartic acid which form NAA and coA. This hydrolysis of NAAG releases
glutamate and NAA.

The main breakdown enzyme for NAA is aspartocyclase

(ASPA). NAA is hydrolyzed by ASPA into aspartate and a carboxylate, typically
acetate.

NAA reacts with glutamate to form NAAG by the enzyme NAAG

Synthetase encoded by RIMKLB. To determine if the elevation in NAA was
associated with its accumulation or its breakdown, we determined patient gene
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expression levels of NAT8L, FOLH1, and NAALAD2 as the NAA accumulation
genes. ASPA and RIMKLB gene expression levels were evaluated as the NAA
breakdown genes (Figure 10). NAA levels was strongly correlated with NAT8L gene
expression levels (r= 0.52, p<0.0001), FOLH1 was weakly correlative (r= 0.25,
p= 0.017), and NAALAD2 was weakly negatively correlative (r= -0.24, p= 0.023).
ASPA and RIMKLB had no correlation with NAA levels. This suggests that high
NAA levels in ovarian cancer are driven by up-regulation of its biosynthesis NAT8L.
Furthermore, the low levels of its substrate aspartate in ovarian cancer further
suggest that NAA biosynthesis as the cause of high NAA levels (Figure 11).
One possibility of elevated NAA is due to global up-regulation of N-acetylation
across various amino acids.

However, our metabolic profile did not show a

consistent pattern of elevated N-acetyl amino acids (Table 6). In fact, aspartic acid
was disproportionately more N-acetylated than all of the N-acetylated amino acids
in ovarian cancer. This suggests that elevated NAA is not a result of global Nacetylation processes of amino acids; rather, there is a significant selection for Nacetylation of aspartic to form NAA in ovarian cancer.
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Table 6. Fold change N-acetylation of amino acids in ovarian cancer. Fold
change is relative intensity of ovarian cancer over the normal ovary.
[red box= up regulation(p<0.05), green box= down regulation (p<0.05)]
N-acetylated
Amino Acid
Fold Change
Fold change
amino acid
serine
1.03
N-acetylserine
0.88
threonine
1.1
N-acetylthreonine
1.6
alanine
1.35
N-acetylalanine
0.91
N-acetylaspartate
aspartate
0.71
28.38
(NAA)
glutamate
1.14
N-acetylglutamate 4.62
tryptophan
0.87
N-acetyltryptophan 0.65
methionine
0.97
N-acetylmethionine 0.76
ornithine
0.48
N-acetylornithine
0.8
putrescine
3.72
N-acetylputrescine 2
glycine
1.27
N-acetylglycine
0.7
To validate that NAA levels were significantly higher in ovarian cancer
compared to the normal ovary, we evaluated a separate cohort of ovarian cancer
(n=47) and normal ovarian samples (n=3) using NMR spectroscopy. NMR also has
the advantage of giving exact quantification of metabolite concentrations. Indeed,
the NAA peak at 2.0-2.1 ppm was distinctly seen in ovarian cancer samples, and
absent in the normal ovary (Figure 12a). Ovarian cancer samples had significantly
higher levels of NAA compared to the normal ovary (Figure 12b) with concentrations
on average at 104.2 µM (±14.57 SEM), and NMR could not detect any NAA in
normal ovaries (p<0.0001).
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Figure 9. Schema of the NAA-NAAG pathway. NAA is biosynthesized by
aspartate N-acetyltransferase (NAT8L) from acetyl CoA (Ac-CoA) and aspartate.
NAA is metabolized into acetate and aspartate by aspartoacyclase (ASPA). NAA
can also form NAAG by reacting with glutamate by the enzyme NAAGS encoded by
RIMKLB gene. NAAG can also revert back to NAA and glutamate by the enzymes
GCP-II encoded by FOLH1 or by GCP-III encoded by NAALAD2.
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Figure 10. NAT8L is strongly correlated with NAA levels in ovarian cancer.
Spearmon’s correlation (r ) of relative NAA levels in 101 ovarian cancer patients
and patient gene expression levels of the NAA pathway.
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Figure 11. Low levels of aspartic acid in ovarian cancer. Aspartate levels of 101
ovarian cancer samples and 15 normal ovary samples shows lower levels of
aspartate in ovarian cancer compared to the normal ovary.
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Figure 12. NMR spectroscopy: higher levels of NAA in ovarian cancer. a.)
NMR spectra of 3 ovarian cancer samples and 2 normal ovary samples shows the
distinct NAA peak in ovarian cancer. (blue, purple, red color spectra= 3 ovarian
cancer samples; black and green color spectra= 2 normal ovary samples) b.) NMR
spectroscopy of NAA samples showing the levels of NAA in 69 ovarian cancer
samples and 10 normal ovaries.
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Clinical implications of NAA biosynthesis
On the basis of substantial elevations in NAA observed in ovarian cancer, we
next wondered if there were any clinical implications of these elevations.

We

investigated the relative NAA levels of 101 ovarian cancer samples using GC/LC
mass spectrometry.

Patients with higher levels of NAA had worsening overall

survival compared to patients with low NAA levels (Figure 13). High NAA overall
survival was 1295 days and low NAA survival was not reached (p=0.038).

Figure 13. High NAA levels are associated with worsening overall
survival in ovarian cancer. Kaplan-Meier analysis of relative NAA levels and
overall survival in 101 ovarian cancer patients.
On the basis of NAA levels being strongly correlated with NAT8L gene
expression, we next examined clinical outcomes of 485 patients based on NAT8L
gene expression from the TCGA.

Analysis of RNASeq gene expression data

revealed that high expression of NAT8L (cut-off > 0.5 z-score) is associated with
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worse overall survival in high grade serous ovarian cancer (Figure 14a).

The

median overall survival of the high NAT8L expression was 35 months compared to
45 months in the low NAT8L group (p=0.031). To validate, we analyzed a second
independent cohort of 285 ovarian cancer patients (Figure 14b). Concordantly, high
NAT8L (cut-off > 47th percentile) gene expression was associated with worse
overall survival compared to the low NAT8L gene expression group. The median
overall survival of the high NAT8L expression were 40 months compared to 52
months in the low NAT8L group (p= 0.005). Finally, we evaluated mRNA levels of
NAT8L in a cohort of ovarian cancer patients from our institution (n= 135) and
normal non-cancerous ovaries (n= 15). Ovarian cancer patients had over a 3 fold
increased levels of NAT8L expression compared to the normal ovary (p<0.001)
(Figure 15).
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Figure 14. High NAT8L gene expression is associated with worse overall
survival. a.) Kaplan Meier analysis of NAT8L gene expression and overall survival
using RNASeq platform in TCGA. b.) Kaplan Meier analysis of NAT8L gene
expression and overall survival from Tothill gene expression database.
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Figure 15. NAT8L gene expression is significantly higher in ovarian cancer.
RT-PCR of NAT8L gene expression comparing ovarian cancer samples (n=135) to
normal ovary samples (n=15). Mean RQ values ± SEM.
To determine if NAT8L protein levels were also significantly elevated in
ovarian cancer and the normal ovary, we examined 209 ovarian cancer patients and
10 normal ovary tissues from our institution using immunohistochemistry of antiNAT8L protein in a tissue microarray. We found significantly higher expression of
NAT8L compared to the normal ovary (Figure 16). Based on a semi-quantitative Hscore method, ovarian cancer had a 1.92 fold higher levels of NAT8L staining
compared to the normal ovary (p<0.0001). Furthermore, higher NAT8L staining was
associated with poor overall survival in ovarian cancer (Figure 17). High NAT8L
expression was associated with 3.86 years overall survival compared to 9.09 years
with low NAT8L expression (p<0.001).
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Figure 16.
Ovarian cancer has significantly higher NAT8L protein levels
compared to the normal . Immunohistochemistry of anti-NAT8L in 208 ovarian
cancer samples and 10 normal ovarian samples. *=p<0.001.
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.
Figure 17. High NAT8L protein levels are associated with worse overall
survival in ovarian cancer. Kaplan-Meier analysis of NAT8L protein expression
and overall survival in 208 ovarian cancer samples.
On the basis that high NAT8L up-regulation is driving NAA accumulation in
ovarian cancer; we considered the relative NAT8L gene expression across various
cancer types in the TCGA. We evaluated the relative gene expression levels and
copy number alterations of NAT8L from across the 20 cancer types. Surprisingly,
we found relatively high levels of NAT8L expression in HSOEC, skin cutaneous
melanoma; glioblastoma multiforme (GBM), kidney chromophobe, and brain lower
grade glioma cancer having the highest expressions of NAT8L in the TCGA (Figure
18) (Table.

Breast, uterine endometroid, and thyroid cancer also had relatively

high NAT8L expression among the 20 tumors assessed from the TCGA. NAT8L
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copy number alterations distinctly showed that ovarian cancer had the greatest
degree of copy number alterations among the 20 cancer types (Figure 19).

Figure 18. NAT8L gene expression across 20 different tumor types. Gene
expression data of NAT8L Log2 normalized from TCGA.
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Table 7. TCGA acronymns for figure 18 and 19.
Acronymn
BRCA
KIRC
COAD, READ
UCEC
GBM
LUSC
OV
LUAD
HNSC
THCA
SKCM
STAD
BLCA
LGG
CESC
LAML
DLBC
ESCA
KIRP
LIHC
PAAD
PRAD

Tumor Type
Breast cancer
Renal clear cell
Colon and Rectal adenocarcinoma
Endometrial Cancer
Glioblastoma multiforme
Lung squamous carcinoma
Ovarian
Lung adenocarcinoma
Head and neck squamous cell
carcinoma
Pappillary thyroid cancer
Cutaneous melanoma
Stomach adenocarcinoma
Bladder cancer
Lower grade glioma
Cervical
Acute Myeloid leukemia
Diffuse large B cell lymphoma
Esophageal carcinoma
Papillary kidney
Liver
Pancreatic adenomcarcinoma
Prostate adenocarcinoma
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Figure 19. NAT8L copy number alterations across 20 types. TCGA Copy
number alterations Log2 transforemed.
Based on the fact that NAT8L gene expression levels were comparatively
high across several tumor types, we evaluated the TCGA database to determine if
high NAT8L affects clinical outcomes in other cancer types. Using the publically
available website www.cbioportal.org, TCGA survival data for NAT8L was analyzed.
TCGA currently does not have melanoma survival data, therefore we analyzed two
different patient cohort gene arrays in melanoma.

Profoundly, high NAT8L

expression was found to have worse overall survival in invasive breast, lung
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squamous, colon, uterine, melanoma and kidney renal cell cancers (Figure 20).
Thus suggesting that worsening survival due to elevated NAA biosynthesis is not
unique only to ovarian cancer.

Figure 20. High NAT8L with worse overall survival in several cancer types.
NAT8L gene expression data from TCGA (breast cancer, lung squamous, colon
adenocarcinoma, uterine endometrioid carcinoma, renal cell carcinoma) and
melanoma gene expression from previously published database [167-168].
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Biologic significance of NAA synthesis
To determine the biological significance of NAA biosynthesis in ovarian cancer,
we next screened the CCLE and NCI-60 database to identify cell lines and cancer
types with high NAT8L expression. Indeed in the CCLE, ovarian cancer cell lines
had some of the highest expressions of NAT8L (Figure 21). We also analyzed the
NCI-60 cell lines, the median (±S.D.) NAT8L expression level of all 60 cancer lines
was 4.45(±0.81) GCRMA. Melanoma, lung, renal, and ovarian cancer cell lines had
some of the highest expression of NAT8L (Figure 22).
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Figure 21. Gene expression of NAT8L from CCLE. Gene expression of cell
lines clustered by cancer type. Numbers in paraenthesis after each cancer type are
the number of cell lines.
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Figure 22. NCI-60 cell lines with high NAT8L gene expression (sorted by top
50%). LC= lung cancer, ME= melanoma, RE= renal, OV= ovary, CO= colon cancer,
PR=prostate cancer, BR=breast, LE=leukemia.

To determine the effects of NAT8L inhibition in cancer cells, siRNA was used to
reduce NAT8L levels in cancer cell lines. To confirm NAT8L knockdown, transient
transfection of several ovarian (HEYA8, SKOV3, A2780) and melanoma cell lines
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(UACC 257, UACC 62, and M14) caused 60-96% knockdown of NAT8L gene
expression at 48 hours (Figure 23).

Figure 23. siRNA NAT8L knockdown of NAT8L gene expression in ovarian
and melanoma cancer cell lines. Gene expression levels of NAT8L detected by
RT-PCR. RQ= relative real time quantitation. Values are mean±SEM.
We next evaluated the effect of NAT8L knockdown on cancer cell growth and
survival.

We selected HEYA8 and A2780 cell lines in ovarian cancer as they had

the highest knockdown of NAT8L using siRNA. First, we evaluated the effect of
NAT8L knockdown on cell viability (Trypan blue) after one [72 hours(3 days)] and
two [144 hours(6 days)] rounds of transfections (Figure 24). After the one round,
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cell viability was decreased by 9.4% by siRNA NAT8L compared to the control nontarget siRNA (siRNA NT) (p<0.003). After two rounds of transfections, cell viability
was decreased by 24.0% by siRNA NAT8L compared to siRNA NT (p<0.01). We
also analyzed a synthetic lethality screen for chemotherapy resistant cell lines
A2780-CP, HEYA8-MDR, and SKOV3-TR. Surprisingly, after one round NAT8L
knockdown and chemotherapy at 120 hours (Day 5), we saw a significant decrease
in cell viability in all three chemo-resistant cell lines (Figure 25). Thus, the effect of
NAT8L knockdown in cancer cell viability using siRNA appears to occur after 5 days
of treatment.

Therefore, we performed the remainder of our in vitro siRNA

% c e ll v ia b ility

experiments with two rounds of transfections unless noted otherwise.

Figure 24. Effect of siRNA NAT8L on cancer cell viability after one and two
rounds of transfections. Values are mean ±SEM.
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Figure 25. Cell viability with siRNA NAT8L compared to siRNA NT
chemotherapy resistant cell lines. Values are mean ±SEM.

in

Trypan blue stains cells that are either dead or have damaged cell
membranes; therefore we investigated if NAT8L knockdown increased cellular
apoptosis. Indeed, HEYA8 and A2780 showed that siRNA NAT8L had a significant
increase of total apoptosis compared to siRNA NT by 38.53% (p<0.001) and
37.85% (p<0.001), respectively (Figure 26). To evaluate the in vitro generalizability
of siRNA NAT8L, melanoma cell lines UACC 257, UACC 62, and M14 similarly
showed an increase in apoptosis consistent with findings in ovarian cancer cell lines
(Figure 27).

Furthermore, knockdown of NAT8L in combination with paclitaxel

treatment displayed a synergistic effect on apoptosis (Figure 28). Cells treated with
paclitaxel and siRNA NAT8L had a 29.83% increase in apoptosis compared to
paclitaxel and siRNA NT treated cells (p<0.001).
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Figure 26. Knockdown of NAT8L increases apoptosis in ovarian cancer cells.
Values are mean ±SEM. *= p<0.001.
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Figure 27. Knockdown of NAT8L increases apoptosis in melanoma cancer
cells. Values are mean ±SEM. *= p<0.001.

.
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Figure 28. Knockdown of NAT8L increases sensitivity of paclitaxel’s effect on
ovarian cancer cell apoptosis. Values are mean ±SEM. *= p<0.001
On the basis that NAT8L is a putative GCN5 related gene (GCN5 is a
ubiquitous histone acetyltransferase that promotes transcriptional activation), we
investigated if NAT8L knockdown has an effect in cancer cell proliferation and cell
cycle progression.

Indeed, ovarian cancer cells treated with siRNA NAT8L had a

significantly decreased cell proliferation compared to siRNA NT (Figure 29a).
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Proliferation decreased by 23.65% (p<0.001) and 19.13% (p<0.001) in A2780 and
HEYA8 cells, respectively. Furthermore, cells treated with siRNA NAT8L decreased
cell cycle progression compared to siRNA NT.

HEYA8 cells with down-regulated

NAT8L had an 8.4% increase in the number of cells with G1 phase (p<0.001), and
an 11.65% decrease in the number cells in the S phase (p<0.001) (Figure 29b).
Thus, knockdown of NAT8L decreased ovarian cancer cell’s ability to proliferate and
progress through the cell cycle suggesting that NAT8L acetylation may have
functions similar to histone acetyltransferases to promote transcriptional activation.
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Figure 29. Knockdown of NAT8L decreases cell proliferation and cell cycle
progression. Values are mean ±SEM. *= p<0.001
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On the basis that one of the proposed functions and association of NAA
biosynthesis in the human brain is in cell energy production, we hypothesized that
knockdown of NAT8L would decrease the levels of ATP in cancers cells.

We

observed a significant decrease in ATP and ADP levels in HEYA8 cells treated with
siRNA NAT8L, and a decrease of ADP in A2780 cells (Figure 30). ATP levels
decreased by 20.8% (p=0.03) in HEYA8 cells. In A2780, although ATP levels were
decreased by 13%, this was not statistically significant (p=0.17). ADP levels were
decreased by 19 %( p<0.001) and 32% (p= 0.002) in HEYA8 and A2780 cells,
respectively.

Figure 30. The effect of siRNA NAT8L on intracellular ATP and ADP. Values
are mean ±SEM.
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Due to the decreased ATP and ADP levels in siRNA NAT8L, we hypothesized that
this catabolic switch would significantly decrease cancer cell’s metastatic potential.
Indeed, knockdown of NAT8L in HEYA8 cells significantly decreased migration and
invasion by 91% and 92%, respectively (p<0.001) (Figure 31).

.
Figure 31. Knockdown of NAT8L significantly decreased migration and
invasion Values are mean ±SEM.
To better understand the consequences of inhibiting NAA production on cancer
cell gene and protein signaling, we evaluated siRNA NAT8L knockdown in HEYA8
cells using a high throughput antibody based reverse phase protein array (RPPA)
and high throughput gene expression array. We used HEYA8 cell lines due to the
fact that there was 96% knockdown of NAT8L from the siRNA, and its robust
therapeutic response. From our RPPA analysis, one of the largest effects of siRNA
NAT8L was inhibition of negative cell death regulation, and increase in regulation of
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kinase activity (Figure 32A). One of the largest effects was down-regulation of AKT
phosphorylation at Serine 479 and Threonine 308 suggesting that the anabolic and
tumorigenic effects of this major oncogenic kinase were abrogated (Figure 32A).
Furthermore in this network, significant inhibition in regulation of cell localization is
predicted with decreases in paxillin, fibronectin, PKC-α, and Src phosphorylation at
Y416 and Y527, thus suggesting decreased metastatic potential in cancer cells. In
the network of regulation of kinase activity, AMPK (PRKAA1) phosphorylation at
Threonine 172 was dramatically higher with NAT8L knockdown. Furthermore, there
was high phosphorylation of acetyl-coA carboxylase (ACC) at residue position
serine 79 which inhibits its activity (Figure 32A). AKT is a major negative regulator
of AMPK. This indicates that knockdown of NAT8L switches HEYA8 cancer cells
from an anabolic state to a catabolic state. Since ACC is the major rate limiting
enzyme reaction for de novo lipid synthesis, we evaluated the effect NAT8L
knockdown on the cell’s fatty acid levels. Cells were transfected with siRNA NAT8L
lead to a dramatic decrease in cell fatty acids compared to NT siRNA (Figure 32B).
NAT8L siRNA caused a 67.7% decrease of fatty acid levels compared to the NT
siRNA (p=0.0004).

85

Figure 32. Knockdown of NAT8L up-regulates switches cell to a catabolic
state and decreases de novo lipogenesis. Red boxes = upregulation, green
boxes= down regulation, black boxes = no change. Red circle = upregulation of
protein levels, Yellow circle = upregulation of protein phosphorylation, Green ciricle=
down regulation of protein levels, blue circle = down regulation of phosphorylation of
protein. *=p<0.001.
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Hierarchical cluster analysis of integrated gene expression from siRNA
NAT8L and siRNA NT had 1961 significantly different gene expression data
(p<0.001) (Figure 33). Network analysis showed significant decreases in a large
number of genes involved in mitosis and the M phase of the cell cycle.

On the

other hand, a number of genes involved in the catabolic processes were upregulated with NAT8L knockdown.

These gene and protein expression results

indicate that one of the major roles of NAA biosynthesis involves regulation of cell
division and growth in mitosis, and the absence of NAA biosynthesis confers a
catabolic process in cancers cells decreasing its potential for proliferation,
metastasis, and survival.
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Figure 33. Knockdown of NAT8L involves the negative regulation of cell
division/mitosis and positive regulation of catabolic genes. Green boxes=
down regulation of gene expression, Red boxes= up regulation of gene expression.
Red circle = upregulation of gene expression levels, Green ciricle= down regulation
of protein levels.
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Effect of NAA biosynthesis in orthotopic ovarian cancer mouse model
On the basis of the clinical and in vitro findings, we evaluated the effect of siRNA
NAT8L in orthotopic ovarian cancer models. As compared to mice treated with
siRNA NT, those treated with siRNA NAT8L had significantly decreased tumor
growth (Figure 34a). A2780 and HEYA8 orthotopic ovarian cancer model had an
84.14% (p<0.001) and 69.17% (p<0.01) decrease in tumor weight, respectively.
A2780 and HEYA8 mouse models also had statistically significant two-three fold
reduction in the number of intraperitoneal tumor nodules. We also observed a
synergistic effect of siRNA NAT8L and paclitaxel (Figure 34b).

Using the HEYA8

orthotopic in vivo model, siRNA NAT8L + paclitaxel had significantly less tumor
burden compared to siRNA NT(p<0.001), paclitaxel + siRNA NT (p= 0.004), and
siRNA NAT8L alone (p= 0.032). We also observed a decrease in the number of
intraperitoneal tumor nodules with siRNA NAT8L + paclitaxel compared to siRNA
NT (p= 0.008), and siRNA NT + paclitaxel (p= 0.020); however, no difference was
observed between siRNA NAT8L alone and siRNA NAT8L + paclitaxel (p= 0.611).
To validate our in vitro data where siRNA NAT8L had significant effect on cell
proliferation and apoptosis, we performed immunohistochemistry of ki67 and
caspase-3 from our in vivo models. Consistent with the in vitro findings, HEYA8
tissues treated with siRNA NAT8L had significantly less proliferation (p<0.001)
(Figure 35), and significantly more apoptosis (Figure 36).

IHC staining using

cleaved-caspase 3 was increased by 2.46 fold in siRNA NAT8L compared to siRNA
NT (p= 0.003) (Figure 36a). Although siRNA NAT8L + paclitaxel had a 1.57 fold
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increase in apoptosis compared to paclitaxel treatment alone, this was not
statistically significant (p=0.19) (Figure 36b).

Figure 34. Effect of siRNA NAT8L treatment in orthotopic ovarian cancer
mouse models. Values are mean ±SEM.
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Figure 35. Effect of siRNA NAT8L on cell proliferation in HEYA8 orthotopic
mouse model. Values are mean ±SEM.
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Figure 36. Effect of siRNA NAT8L +/- paclitaxel on apoptosis in HEYA8
orthotopic mouse model. Values are mean ±SEM.
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To test the specificity and any possible off target effect of NAT8L siRNA, we
did an experiment with two separate sequences of NAT8L siRNA in SKOV3
orthotopic mouse model. Our results showed that both NAT8L siRNA significantly
reduced tumor burden. Our first sequence and second sequences decreased tumor
burden by 70% and 76%, respectively (Figure 37). Furthermore, there were no
significant differences in tumor burden between either NAT8L siRNA sequences.

Figure 37. SKOV3 orthotopic ovarian cancer mouse model. Mice treated with
DOPC NAT8L siRNA using two different sequences. Values are mean ±SEM.
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To evaluate the generalizability of NAT8L siRNA , we evaluated its effect in
an A375-SM orthotopic melanoma mouse model. Mice treated with NAT8L siRNA
had a 62% decrease in tumor burden than the control mice. This indicates that
NAT8L siRNA decreases tumor growth in melanoma cancer by inhibiting NAA
production.
.

Figure 38. A375-SM orthotopic melanoma mouse model. Mice treated with
DOPC NAT8L siRNA and NT (control) siRNA. Values are mean ±SEM.
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Discussion
Clinical Relevance of NAA production
Our study is the largest metabolomics profile of high grade serous epithelial
ovarian cancer (HGSOC) to date.

We observed an increase in glycolytic

intermediates seen in the “Warburg effect”.

Furthermore, nearly 75% of the

alterations involved lipid and amino acid pathways. One of the most drastic upregulations involved is the neuron biosynthesized NAA metabolite which is derived
from acetylation of aspartic acid which we detected in cultured ovarian cancer cells.
More importantly, high levels of NAA and its biosynthetic enzyme NAT8L leads to
worsening patient survival.

We observed that knockdown of NAT8L leads to

significant decreases in tumor growth in an in vitro setting by decreasing tumor
proliferation, cell cycle progression, increasing cellular apoptosis, and decreasing
cancer cell invasion.

In the In vivo setting, siRNA NAT8L decreased tumor

proliferation and increased apoptosis. These findings along with the worsening
clinical outcomes associated with high NAT8L gene expression in melanoma,
breast, colon, lung squamous, renal clear cell, and uterine endometrial cancers
provide compelling evidence that NAA production confers oncogenic properties, and
functions as an oncometabolite.
The overwhelming majority of metabolites altered in HGSOC involved lipid and
amino acid metabolic pathways when compared to the normal ovary. Eicosanoids
and phospholipids were some of the highest fold changes in HGSOC highlighting
the need for pro-inflammatory and pro-proliferative components. PGE2 is the most
up-regulated eicosanoid in HGSOC tissues.
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PGE2 is the most abundant

prostaglandin in various cancers, and high levels are associated with worsening
outcomes [183,184,185]. In colon cancer, PGE2 contributes to tumor growth by
DNA methylation [186]. Interestingly, some essential diet derived fatty acids were
elevated indicating, in addition to de novo lipogenesis, ovarian cancer cells also rely
on the absorption of fatty acids from their microenvironment. This is in accordance
with a recent study showing that breast and prostate cancers absorb diet derived
fatty acids to promote tumor growth and proliferation[187]. In ovarian cancer tumors
metastasized to the omentum, up-regulation of Fatty Acid Binding Protein 4
(FABP4) has been shown to significantly affect tumor growth and metastasis [123].
Thus, emphasizing the importance of fatty acid uptake in ovarian cancer.
Amino acid metabolism was the second most altered pathway in ovarian cancer
with some of highest increases involving metabolites in the alanine/aspartate,
glutamate/glutamine, and phenylalanine/tyrosine pathways suggesting that these
are important amino acid pathways in HGSOC pathophysiology. There is emerging
evidence that many cancers have dysregulated amino acid metabolism that lead to
tumor aggressiveness. For example, cancer cells can divert glycolytic carbons into
serine and glycine metabolic pathways [188]. The serine pathway has been found
recently to be a major route for the conversion of glutamine to alpha-ketoglutarate
for analeperosis in the TCA cycle to support tumor growth [66]. Glycine is used for
de novo purine nucleotide synthesis in cancer cells [64].
Our analysis of HGSOC amino acid pathways showed that NAA involved in the
aspartate/alanine pathway to be the most up regulated metabolites. The high upregulation of NAA in ovarian cancer compared to the normal ovary is consistent with
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recent metabolomics studies [162,163,189]. In a study by Fong et al, NAA was
elevated in primary ovarian cancer and even in greater amount in omental
metastatic tumors compared to the normal ovary [162]. Interestingly, the primary
ovarian cancer samples were from stage I-IIIC patients and omental metastatic
tumors were from stage IIIC-IV patients suggesting that higher levels of NAA would
be detected in more advanced cancers. In a study by Ben Sellem et al, NMR
analysis of serous, endometrioid, and mucinous cancers compared to the normal
ovary showed specifically highest up-regulation of NAA in serous ovarian cancers.
Furthermore, partial least square discriminant analysis showed a clear separation
of high grade (grade III) serous ovarian cancers from the normal ovary when
compared to grade I and II [189]. In a study by Kolwijck et al, aspiration of ovarian
cyst fluid (OCF) from serous, mucinous, endometrial, and clear cell ovarian cancers
showed that serous ovarian cancer had the largest concentrations of NAA.
Furthermore, regardless of subtypes, patients with higher concentrations of NAA in
OCF had more advanced stage disease (Stage III-IV).

Interestingly, NAA

concentrations of OCF were also comparable to the malignant ascites levels[163].
All of these studies suggest that high levels of NAA are associated with more
advanced disease in ovarian cancer and the results of our study is the first direct
evidence that high levels of NAA are in fact associated with worsening outcomes in
HGSOC.
However, some of our data differ from these previous studies [162,163,189].
For example in our study of primary ovarian cancer samples (POC), NAA was upregulated 28 fold vs. 3 fold in the study by Fong et al [162] when compared to the
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normal ovary. Our POC were primarily from patients with advanced stage high
grade epithelial ovarian cancers (Stages III-IV). Fong et al’s POCs were mostly
early stage ranging from Stage I-III.

However, when they compared omental

metastatic ovarian tumors (Stage IIIC-IV) to the normal ovary, they detected a
dramatically 85 fold increase in NAA suggesting more aggressive tumors have
higher

levels

of

NAA.

Second,

the

histopathologies

of

their

ovarian

adenocarcinomas were not specified, therefore making the metabolomics
comparison to our HSOEC difficult. Finally, our sample size of POC was larger with
71 patients compared to 11 patients in their study. In the study by Kolwijck et al,
aspiration from OCF did detect NAA in serous borderline and benign tumors, and
they did not detect a difference between NAA concentration in OTC between the
malignant, borderline, or benign serous tumors[163]. There are several issues with
interpretation and comparisons with our study. First, this study was done in cystic
fluid, and no tumor tissue was evaluated so it would be difficult to say where the
source of NAA levels in serous borderline and benign tumors would be. Second,
there were only 9 serous ovarian cancer patients OTC evaluated, and no details
about the grade of the tumor were available.

However, the authors did find

significantly higher concentration of NAA in advanced stage disease compared to
early stage disease. This suggests that higher levels of NAA would be associated
with worsening prognosis.

As we have shown in multiple large cohorts of ovarian

cancer patients, at the gene-protein-metabolite level, high NAA production is
significantly associated with worsening outcomes in HGSOC.
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Biologic relevance of NAA production
This was the first time that the effects of NAT8L knockdown have been reported
in cancer cells. We observed that the knockdown of the NAT8L leads to significant
decreases in tumor growth in the in vitro and in vivo setting by decreasing tumor
proliferation, cell cycle progression, invasion/migration, and increasing cellular
apoptosis.

Furthermore, knockdown of NAT8L resulted in up-regulation of the

major metabolic regulator AMPK, and decreased activity of AKT and ACC in HEYA8
ovarian cancer cells. Metabolically, NAT8L knockdown decreased fatty acid levels
in the cancer cell.

These results suggest that abrogation of NAA biosynthesis

switches cancer cells from an anabolic to a catabolic state, thus decreasing
cancer’s ability to proliferate and become more susceptible to cell death.
It is noteworthy that similar results of tumor inhibition by activating the catabolic
state in tumors by activating AMPK activity. Drugs such as metformin have shown
to activate AMPK activity, and cause cell cycle arrest and decreased cell
proliferation in various cancers [124], metformin treated of several ovarian cancer
cell lines caused cell cycle arrest and decreased cell proliferation.

Metformin

caused a significant increase in AMPK phosphorylation and ACC phosphorylation
enhancing fatty acid beta-oxidation and decreased lipid synthesis. Interestingly,
metformin’s anti-proliferative effects were seen both through an AMPK dependent
and independent pathways. In another study by Rattan et al [190], A2780 ovarian
cancer orthotopic mice treated with metformin resulted in significant reduction of
tumor growth with decreased tumor cell proliferation.

Furthermore, metformin

significantly increased cisplatin cytotoxicity. Moreover, the metformin treated group
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had significantly increased activation of AMPK. In a study of the ovarian cancer
cells SKOV3 [191], the FASN inhibitor drug C93 caused significant increase in
AMPK activation and a decrease in ACC activity. As a result, fatty acid synthesis
was decreased and glucose oxidation was increased possibly to conserve energy.
This treatment worsened cell redox status causing cell death. Furthermore, C93
treatment of SKOV3 xenograft athymic mice showed significant anti-tumor effects
and apoptosis.
Although siRNA NAT8L treatment had similar effects on AMPK activity as
metformin and C93, there were some differences that we have noted from our
study. The study by Rattan et al [124] showed anti-proliferative effects of metformin
on various ovarian cancer cell lines (with the exception of SKOV3ip cell lines),
unfortunately, no orthotopic model of these cell lines were included as validation in
their study. In a separate study by Rattan et al [190], an orthotopic in vivo model of
A2780 with metformin did show anti-tumor effects. However, there is a shortcoming
for generalizability towards the more common high grade serous ovarian cancer;
A2780 is an endometrioid ovarian cancer cell line. In the study by Zhou et al [191],
the in vivo model was a xenograft model rather than orthotopic model affecting its
generalizability. Furthermore, only one cell line was used for both in vitro and in
vivo therapy. In our study, the therapeutic implications of siRNA NAT8L were tested
in several in vivo models. We evaluated the effect of siRNA NAT8L in high grade
serous and endometroid ovarian cancer cell lines. Furthermore, we evaluated the
effect of siRNA NAT8L in several melanoma cell lines for generalizability.
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Study limitations
Although we show compelling evidence that abrogating NAA production will
have anti-tumor effects by switching cancer cells from a catabolic to anabolic state,
the mechanism of how NAA contributes to cell anabolism and survival remains
unknown at this point. Based on the protein and signaling alteration observed with
knockdown of NAT8L, it would be helpful to profile HEYA8 cells to determine the
metabolomics profile. This would give further insight into the mechanism of how
NAA production affects cancer cells from gene, protein, and metabolic levels.
Another limitation related to the mechanism of NAA functioning in cancer cell is the
question why NAA and NAT8L are elevated in cancer cells. Our investigation is
suggestive that NAA production is advantageous to cancer cells, and identifying the
cause of NAA and NAT8L up-regulation elevation would be compelling to identify.
Another limitation of our study is based on the assumption that high levels of
NAA would be present in other cancers that are associated with worse outcomes
with high NAT8L gene expression.

Although metabolomics profiling of human

cancer tissues remains at its infancy, various metabolomics studies have shown
significant up-regulation of NAA compared in invasive breast cancer and prostate
cancer[65,192].

Furthermore, our clinical outcomes results of high NAT8L gene

expression, and decreased tumor growth in our orthotopic melanoma mouse model
treated with NAT8L siRNA, highly suggest that NAA levels would be high in several
cancers promoting tumor growth.
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Implications
From our study, we observed the increased expression of NAT8L in ovarian
cancer compared to the normal ovary is a characteristic of this disease.
Furthermore, from our clinical analysis, in vitro and in vivo experiments, we show
that targeting NAT8L significantly inhibits tumor growth. Therefore, ovarian cancer
is associated with the genetic up-regulation of the NAA biosynthetic machinery to
promote growth and survival of the tumor.

This unique characteristic of ovarian

cancer not present in the normal ovarian tissue makes targeting NAT8L an
attractive target to abrogating tumor growth and improving patient outcomes by
blocking an important up-regulated cancer metabolic pathway.

A better

understanding of molecular mechanisms of why some cancers are more dependent
on NAA production would help in improving the efficacy of targeting this pathway.
Furthermore, with the distinct elevation of NAA in ovarian cancer, there is
promise that NAA may be used as a biomarker.

With advances of clinical MRS

technology, our metabolic results have implications for the possibility of NAA as a
potential novel biomarker in tumors outside of the CNS.

Recently, the novel

oncometabolite 2-HG was shown to be detected in a non-invasive manner using
MRS in glioma patients with IDH 1 and 2 mutations [193]. NAA would be an ideal
marker in ovarian cancer due to its dramatic elevation compared to the normal
ovary. It would be interesting to see if MRS technology could aid in diagnosis of
ovarian cancer in woman who present with ovarian masses.

Furthermore, the

levels of NAA may be used in MRS techniques to assess response to

102

chemotherapy would be of use to assess. If NAA levels do decrease with therapy in
ovarian cancer, then this holds great promise to use NAA as treatment biomarker.
Finally, our study reveals that NAA is not only unique to brain metabolism, but
also in the metabolism of cancer. Since its discovery in 1956, NAA’s biological role
has remained unclear and elusive. The majority of studies related to NAA are in the
area of NMR spectroscopy and its relationship to human brain pathologies.
Diseases such as multiple sclerosis, cerebral vascular accidents, major head
traumas, certain psychiatric conditions, and Canavan disease are all associated
with deregulated NAA levels.

More studies looking into the biology and

biochemistry is needed to help understand the mechanism of this abundant
metabolite in the human brain and cancers.
In conclusion, our study reveals that metabolic alteration in ovarian cancer
involves mainly lipid and amino acid metabolic pathways.

Targeting unique

pathways such as NAA production seems to have promising effects in abrogating
the results of this metabolic alteration by inhibiting tumor growth and metastasis.
Furthermore, our clinical and biologic studies of several cancer types revealed that
NAA production seems relevant not only in ovarian cancer but also in several
cancers, and further understanding of its mechanism would not only contribute to
understanding of its role in cancer but also further an understanding of its role in the
human brain.
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